false --12-31 Q2 0001716947 P3Y P3Y 2027-12-09 2028-08-07 2025-04-25 0001716947 2024-01-01 2024-06-30 0001716947 2024-08-12 0001716947 2024-06-30 0001716947 2023-12-31 0001716947 2024-04-01 2024-06-30 0001716947 2023-04-01 2023-06-30 0001716947 2023-01-01 2023-06-30 0001716947 us-gaap:CommonStockMember 2023-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001716947 us-gaap:RetainedEarningsMember 2023-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2023-03-31 0001716947 2023-03-31 0001716947 us-gaap:CommonStockMember 2024-03-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001716947 us-gaap:RetainedEarningsMember 2024-03-31 0001716947 us-gaap:NoncontrollingInterestMember 2024-03-31 0001716947 2024-03-31 0001716947 us-gaap:CommonStockMember 2022-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001716947 us-gaap:RetainedEarningsMember 2022-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2022-12-31 0001716947 2022-12-31 0001716947 us-gaap:CommonStockMember 2023-12-31 0001716947 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001716947 us-gaap:RetainedEarningsMember 2023-12-31 0001716947 us-gaap:NoncontrollingInterestMember 2023-12-31 0001716947 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001716947 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001716947 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001716947 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001716947 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001716947 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0001716947 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001716947 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-06-30 0001716947 us-gaap:CommonStockMember 2023-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001716947 us-gaap:RetainedEarningsMember 2023-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2023-06-30 0001716947 2023-06-30 0001716947 us-gaap:CommonStockMember 2024-06-30 0001716947 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001716947 us-gaap:RetainedEarningsMember 2024-06-30 0001716947 us-gaap:NoncontrollingInterestMember 2024-06-30 0001716947 ENSC:EBIRIncMember 2024-06-30 0001716947 ENSC:EBIRIncMember 2020-12-31 0001716947 ENSC:KeyPersonnelMember ENSC:EBIRIncMember 2024-06-30 0001716947 ENSC:UnrelatedPartyMember ENSC:EBIRIncMember 2024-06-30 0001716947 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ENSC:CustomerMember 2024-01-01 2024-06-30 0001716947 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ENSC:CustomerMember 2023-01-01 2023-12-31 0001716947 2023-01-01 2023-12-31 0001716947 2019-09-30 0001716947 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001716947 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001716947 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001716947 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001716947 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001716947 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2023-12-31 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2024-01-01 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsMember 2024-06-30 0001716947 ENSC:MPARMember 2024-04-01 2024-06-30 0001716947 ENSC:MPARMember 2023-04-01 2023-06-30 0001716947 ENSC:MPARMember 2024-01-01 2024-06-30 0001716947 ENSC:MPARMember 2023-01-01 2023-06-30 0001716947 ENSC:TAAPOUDMember 2024-04-01 2024-06-30 0001716947 ENSC:TAAPOUDMember 2023-04-01 2023-06-30 0001716947 ENSC:TAAPOUDMember 2024-01-01 2024-06-30 0001716947 ENSC:TAAPOUDMember 2023-01-01 2023-06-30 0001716947 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001716947 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001716947 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001716947 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001716947 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001716947 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001716947 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001716947 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001716947 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001716947 us-gaap:ConvertibleDebtSecuritiesMember 2024-04-01 2024-06-30 0001716947 us-gaap:ConvertibleDebtSecuritiesMember 2023-04-01 2023-06-30 0001716947 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-06-30 0001716947 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-06-30 0001716947 2020-12-31 0001716947 us-gaap:InvestorMember 2021-07-02 0001716947 us-gaap:InvestorMember 2024-02-12 0001716947 ENSC:TwentyTwentyThreeNotesMember 2024-06-30 0001716947 ENSC:FinancedInsuranceMember 2024-06-30 0001716947 ENSC:FinancedInsuranceMember 2023-12-31 0001716947 ENSC:TwentyTwentyThreeNotesMember 2023-12-31 0001716947 ENSC:TwentyTwentyThreeNotesMember 2024-04-01 2024-06-30 0001716947 ENSC:TwentyTwentyThreeNotesMember 2024-01-01 2024-06-30 0001716947 ENSC:SecuritiesPurchaseAgreementMember 2023-10-22 2023-10-23 0001716947 ENSC:SecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-10-22 2023-10-23 0001716947 ENSC:FirstClosingSecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-10-25 0001716947 ENSC:FirstClosingSecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-10-24 2023-10-25 0001716947 ENSC:SecondClosingSecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-11-29 0001716947 ENSC:SecondClosingSecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-11-29 2023-11-29 0001716947 ENSC:SecuritiesPurchaseAgreementMember ENSC:TwentyTwentyThreeNotesMember 2023-10-23 0001716947 ENSC:SecuritiesPurchaseAgreementMember 2023-10-23 0001716947 ENSC:TwentyTwentyThreeNotesMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001716947 ENSC:SecuritiesPurchaseAgreementMember 2024-01-01 2024-06-30 0001716947 2024-06-01 2024-06-30 0001716947 ENSC:TwentyTwentyThreeNotesMember ENSC:FirstSecuritiesPurchaseAgreementMember 2023-11-29 2023-11-29 0001716947 ENSC:TwentyTwentyThreeNotesMember ENSC:SecondSecuritiesPurchaseAgreementMember 2023-11-29 2023-11-29 0001716947 2021-06-30 0001716947 2023-08-31 0001716947 srt:MinimumMember 2021-06-30 0001716947 srt:MaximumMember 2021-06-30 0001716947 ENSC:PublicWarrantMember 2021-06-30 0001716947 ENSC:PrivateWarrantMember 2021-06-30 2021-06-30 0001716947 us-gaap:SubscriptionArrangementMember 2021-06-30 0001716947 2021-08-03 0001716947 2021-07-02 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-02 0001716947 srt:MinimumMember 2024-06-30 0001716947 2021-09-24 0001716947 2021-11-05 0001716947 ENSC:TwentyTwentyTwoNotesMember 2022-07-31 0001716947 ENSC:TwentyTwentyTwoNotesAndTwoThousandTwentyOneMember 2023-05-12 0001716947 2023-05-12 0001716947 2022-08-09 0001716947 us-gaap:WarrantMember 2023-05-12 0001716947 us-gaap:WarrantMember 2022-12-09 0001716947 us-gaap:WarrantMember 2023-02-06 0001716947 us-gaap:WarrantMember srt:MinimumMember 2023-02-06 0001716947 us-gaap:WarrantMember srt:MaximumMember 2023-02-06 0001716947 ENSC:WarrantOneMember 2023-02-06 0001716947 ENSC:WarrantTwoMember 2023-02-06 0001716947 us-gaap:WarrantMember srt:MinimumMember 2023-05-12 0001716947 us-gaap:WarrantMember srt:MaximumMember 2023-05-12 0001716947 ENSC:SeriesAOneWarrantMember 2023-05-12 0001716947 ENSC:SeriesATwoWarrantMember 2023-05-12 0001716947 ENSC:PlacementAgentWarrantsMember 2023-05-12 0001716947 us-gaap:WarrantMember 2024-02-12 0001716947 2024-02-12 0001716947 us-gaap:WarrantMember 2023-10-25 0001716947 us-gaap:WarrantMember 2023-11-28 0001716947 us-gaap:WarrantMember 2024-01-31 0001716947 2024-01-31 0001716947 us-gaap:WarrantMember ENSC:PlacementAgentWarrantsMember 2024-02-12 0001716947 ENSC:SeriesBWarrantsMember 2024-02-12 0001716947 ENSC:SeriesAWarrantsMember 2024-02-12 0001716947 us-gaap:WarrantMember 2024-02-12 2024-02-12 0001716947 2024-02-12 2024-02-12 0001716947 ENSC:WarrantInducementMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantInducementMember 2024-04-01 2024-06-30 0001716947 ENSC:WarrantOneMember 2024-06-30 0001716947 ENSC:WarrantOneMember srt:MinimumMember 2024-06-30 0001716947 ENSC:WarrantOneMember srt:MaximumMember 2024-06-30 0001716947 ENSC:WarrantOneMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantTwoMember 2024-06-30 0001716947 ENSC:WarrantTwoMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantThreeMember 2024-06-30 0001716947 ENSC:WarrantThreeMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantFourMember 2024-06-30 0001716947 ENSC:WarrantFourMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantFiveMember 2024-06-30 0001716947 ENSC:WarrantFiveMember srt:MinimumMember 2024-06-30 0001716947 ENSC:WarrantFiveMember srt:MaximumMember 2024-06-30 0001716947 ENSC:WarrantFiveMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantSixMember 2024-06-30 0001716947 ENSC:WarrantSixMember srt:MinimumMember 2024-06-30 0001716947 ENSC:WarrantSixMember srt:MaximumMember 2024-06-30 0001716947 ENSC:WarrantSixMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantSevenMember 2024-06-30 0001716947 ENSC:WarrantSevenMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantEightMember 2024-06-30 0001716947 ENSC:WarrantEightMember 2024-01-01 2024-06-30 0001716947 ENSC:WarrantNineMember 2024-06-30 0001716947 ENSC:WarrantNineMember srt:MinimumMember 2024-06-30 0001716947 ENSC:WarrantNineMember srt:MaximumMember 2024-06-30 0001716947 ENSC:WarrantNineMember 2024-01-01 2024-06-30 0001716947 us-gaap:WarrantMember 2024-06-30 0001716947 2022-07-01 0001716947 ENSC:DecemberPublicOfferingMember 2022-07-01 0001716947 ENSC:DecemberPublicOfferingMember 2022-08-09 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2024-06-30 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember 2021-07-02 0001716947 ENSC:LeisureAcquisitionCorpADelawareCorporationMember us-gaap:MeasurementInputExpectedTermMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-07-02 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2024-06-30 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2024-06-30 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2024-06-30 0001716947 ENSC:ShareSubscriptionFacilityMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2024-06-30 0001716947 us-gaap:MeasurementInputExpectedTermMember ENSC:ShareSubscriptionFacilityMember srt:MinimumMember 2024-06-30 0001716947 us-gaap:MeasurementInputExpectedTermMember ENSC:ShareSubscriptionFacilityMember srt:MaximumMember 2024-06-30 0001716947 us-gaap:MeasurementInputPriceVolatilityMember ENSC:ShareSubscriptionFacilityMember srt:MinimumMember 2024-06-30 0001716947 us-gaap:MeasurementInputPriceVolatilityMember ENSC:ShareSubscriptionFacilityMember srt:MaximumMember 2024-06-30 0001716947 us-gaap:MeasurementInputRiskFreeInterestRateMember ENSC:ShareSubscriptionFacilityMember srt:MinimumMember 2024-06-30 0001716947 us-gaap:MeasurementInputRiskFreeInterestRateMember ENSC:ShareSubscriptionFacilityMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-24 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-05 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasuredMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2022-07-01 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2022-07-01 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2022-07-01 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2022-07-01 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-07-01 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputSharePriceMember 2022-08-09 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExercisePriceMember 2022-08-09 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputExpectedTermMember 2022-08-09 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputPriceVolatilityMember 2022-08-09 0001716947 ENSC:LiabilityClassifiedWarrantsGrantDateMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-08-09 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2024-06-30 0001716947 ENSC:LiabilityClassifiedWarrantsRemeasured2Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2023-02-28 0001716947 ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember 2023-08-31 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001716947 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001716947 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001716947 us-gaap:EmployeeStockOptionMember 2024-06-30 0001716947 us-gaap:EmployeeStockOptionMember ENSC:StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember 2024-06-30 0001716947 ENSC:WarrantOutstandingMember 2024-06-30 0001716947 ENSC:SecuritiesPurchaseAgreementMember 2024-06-30 0001716947 us-gaap:WarrantMember 2024-04-25 2024-04-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2024

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number: 001-38306

 

Ensysce Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   82-2755287

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

   92037
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 263-4196

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ENSC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

 

As of August 12, 2024, the registrant had 8,471,172 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 

 
 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will” and “would,” or the negative of these terms or other similar expressions intended to identify statements about the future. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about:

 

  ● our estimates regarding expenses, revenue, capital requirements and timing and availability of and the need for additional financing will almost certainly not match actual amounts and timing;
     
  ● our ability to continue as a going concern for the next twelve months;
     
  ● the risk that our lead product candidate PF614 and PF614-MPAR may not be successful in limiting or impeding abuse, overdose, or misuse or providing additional safety upon commercialization;
     
  ● the need for substantial additional funding to complete the development and commercialization of our product candidates;
     
  ● the risk that our clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties;
     
  ● the risk that the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all;
     
  ● the risk that clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this Quarterly Report on Form 10-Q;
     
  ● the risk that we will be unable to successfully market or gain market acceptance of our product candidates;
     
  ● the risk that our product candidates may not be beneficial to patients or successfully commercialized;
     
  ● the risk that we have overestimated the size of the target market, patients’ willingness to try new therapies, and the willingness of physicians to prescribe these therapies;
     
  ● effects of competition;

 

  ● the risk that third parties on which we depend for laboratory, clinical development, manufacturing, and other critical services will fail to perform satisfactorily;
     
  ● the risk that we will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others;
     
  ● the loss of key members of our management team;
     
  ● changes in our regulatory environment;
     
  ● the ability to attract and retain key scientific, medical, commercial, or management personnel;
     
  ● changes in our industry;
     
  ● our ability to remediate any material weaknesses or establish and maintain effective internal controls over financial reporting;
     
  ● the risk that our common stock will be delisted from Nasdaq;
     
  ● The risk that we may not be able to regain or maintain compliance with applicable listing standards of Nasdaq;
     
  ● other factors disclosed in this Quarterly Report on Form 10-Q; and
     
  ● other factors beyond our control.

 

The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on Ensysce’s current expectations and beliefs concerning future developments and their potential effects on Ensysce. There can be no assurance that future developments affecting Ensysce will be those that Ensysce has anticipated. These forward-looking statements involve risks, uncertainties (some of which are beyond Ensysce’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Moreover, the occurrence of the events described in the “Risk Factors” in our Annual Report on Form 10-K may adversely affect Ensysce. Ensysce will not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

i
 

 

GLOSSARY

 

Definitions:    
2021 Notes   The senior secured convertible promissory notes in the aggregate original principal amount of $15.9 million, sold in two closings on September 24, 2021 and November 5, 2021, respectively, pursuant to the Securities Purchase Agreement entered into on September 24, 2021
2021 Omnibus Incentive Plan   Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan
2022 Notes   The senior secured convertible promissory notes in the aggregate original principal amount of $8.48 million, sold in two closings on June 30, 2022 and August 8, 2022, respectively, pursuant to the Securities Purchase Agreement entered into on June 30, 2022
2023 Notes   The senior secured convertible promissory notes in the aggregate original principal amount of $1.8 million, sold in two closings on October 25, 2023 and November 28, 2023, respectively, pursuant to the Securities Purchase Agreement entered into on October 23, 2023
2022 December Offering   The Company’s December 2022 registered direct offering of common stock (including pre-funded warrants in lieu thereof). The Offering closed on December 9, 2022 for aggregate consideration of $4.1 million
2023 February Offering   The Company’s February 2023 registered direct offering of common stock and private placement warrants for aggregate consideration of $3.0 million
2023 May Offering   The Company’s May 2023 registered direct offering of common stock (including pre-funded warrants in lieu thereof) for aggregate consideration of $7.0 million
2024 Warrant Inducement   The Company’s February 2024 transaction including the cash exercise of certain existing warrants at a reduced price and the issuance of new warrants
Board   Board of directors of Ensysce, or a committee thereof, as applicable
Business Combination   The definitive merger agreement among LACQ, Merger Sub and Former Ensysce, dated January 31, 2021, providing for, among other things, and subject to terms and conditions therein, the business combination between LACQ and Former Ensysce pursuant to the merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and as a wholly-owned subsidiary of LACQ
CMOs   Contract manufacturing organizations
Company   Ensysce Biosciences, Inc. and its consolidated subsidiaries
COVID-19   Novel coronavirus disease
Covistat   A subsidiary renamed EBIR, Inc.
CROs   Contract research organizations
EBIR   Previously known as Covistat, Inc., EBIR, Inc. is a clinical stage pharmaceutical company that is developing a compound utilized in the Company’s overdose protection program for the treatment of COVID-19 and 79.2%-owned subsidiary of the Company
Ensysce   Ensysce Biosciences Inc.
Exchange Act   Securities Exchange Act of 1934, as amended
FDA   United States Food and Drug Administration
Former Ensysce   Ensysce Biosciences, Inc., a Delaware corporation, prior to the consummation of the merger with and into Merger Sub
GAAP   Generally Accepted Accounting Principles in the United States of America
GCP   Good Clinical Practices
GEM Agreement   Share Purchase Agreement between the Company, GEM Global, and GYBL, dated as of December 29, 2020, including a Registration Rights Agreement between the same parties and dated as of the same date
GEM Global   GEM Global Yield LLC SCS
GEM Warrants   4,608 shares of common stock that may be issued upon the exercise of warrants issued to GYBL under the terms of the GEM Agreement at an exercise price of $1.06 per share

 

ii
 

 

GYBL   GEM Yield Bahamas Limited
Inducement Letter   Inducement offer letter entered into with certain holders of existing warrants to purchase 3,601,752 shares of the Company’s common stock (issued on May 12, 2023) to reduce the exercise price from $3.637 per share to $1.31 per share.
Investor Notes   The 2021 Notes, 2022 Notes and 2023 Notes, collectively
LACQ   Leisure Acquisition Corp., a Delaware Corporation
LACQ Warrants   Warrants that relate to the Business Combination or were issued prior to it and are exercisable for 21,993 shares of our common stock at a weighted average exercise price of $2,725.90 per share
Merger   The merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and a wholly owned subsidiary of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger.
Merger Agreement   Agreement and Plan of Merger, dated as of January 31, 2021, by and among LACQ, Merger Sub and Former Ensysce, providing for, among other things, and subject to the terms and conditions therein, a business combination between Former Ensysce and LACQ pursuant to the proposed merger of Merger Sub with and into Former Ensysce, with Former Ensysce surviving the transaction as a wholly-owned subsidiary of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger
Merger Sub   EB Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of LACQ prior to the consummation of the Merger
MPAR Grant   Research and development grant related to the development of its MPAR® overdose prevention technology awarded to the Company by NIH through NIDA in September 2018
Nasdaq   The Nasdaq Stock Market LLC
NIDA   National Institute of Drug Abuse
NIH   National Institutes of Health
OUD Grant   Research and development grant related to the development of its TAAP/MPAR® abuse deterrent technology for Opioid Use Disorder awarded to the Company by NIH/NIDA in September 2019
Prior Warrants   Warrants issued pursuant to the Securities Purchase Agreement. The Prior Warrants issued in (i) 2021 are exercisable for an aggregate of 4,518 shares of our common stock at an exercise price of $3.64 per share and in (ii) 2022 are exercisable for an aggregate of 38,900 shares of our common stock at an exercise price of $3.64 per share
Public Warrants   The redeemable warrants issued by us and sold as part of the units in the LACQ IPO (whether they were purchased in the LACQ IPO or thereafter in the open market). The Public Warrants are exercisable for an aggregate of approximately 41,666 shares of our common stock at an exercise price of $2,760.00 per share
R&D   Research and Development
SEC   U.S. Securities and Exchange Commission
Securities Act   Securities Act of 1933, as amended
Securities Purchase Agreement   The Securities Purchase Agreement, dated as of September 24, 2021, June 30, 2022, or October 23, 2023 as the context dictates, by and between Ensysce and the institutional investors party thereto
SPA   A Securities Purchase Agreement, dated as of September 24, 2021, June 30, 2022, or October 23, 2023 as the context dictates, by and between Ensysce and the institutional investors party thereto
TAAP   Trypsin Activated Abuse Protection

 

iii
 

 

Table of Contents

 

    Page
     
  Forward-Looking Statements i
  Glossary ii
     
PART I. FINANCIAL INFORMATION 1
     
Item 1. Financial Statements (Unaudited) 1
  Consolidated Balance Sheets 1
  Consolidated Statements of Operations 2
  Consolidated Statements of Changes in Stockholders’ Equity (Deficit) 3
  Consolidated Statements of Cash Flows 4
  Notes to Consolidated Financial Statements (Unaudited) 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
Item 3. Quantitative and Qualitative Disclosures About Market Risk 30
Item 4. Controls and Procedures 30
     
PART II. OTHER INFORMATION 31
     
Item 1. Legal Proceedings 31
Item 1A. Risk Factors 31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31
Item 3. Defaults Upon Senior Securities 31
Item 4. Mine Safety Disclosures 31
Item 5. Other Information 31
Item 6. Exhibits 32
Signatures 33

 

iv
 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Ensysce Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

 

   June 30, 2024   December 31, 2023 
Assets          
Current assets:          
Cash and cash equivalents  $1,043,231   $1,123,604 
Unbilled receivable   224,223    97,561 
Prepaid expenses and other current assets   1,192,283    1,067,703 
Total current assets   2,459,737    2,288,868 
Other assets   335,883    419,217 
Total assets  $2,795,620   $2,708,085 
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $481,971   $1,936,007 
Accrued expenses and other liabilities   370,186    542,260 
Notes payable and accrued interest   454,463    854,697 
Total current liabilities   1,306,620    3,332,964 
Long-term liabilities:          
Liability classified warrants   9,615    26,388 
Total long-term liabilities   9,615    26,388 
Total liabilities  $1,316,235   $3,359,352 
Commitments and contingencies (Note 6)   -    - 
Stockholders’ equity (deficit)          
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2024 (unaudited) and December 31, 2023   -    - 
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2024 (unaudited) and December 31, 2023; 8,151,253 and 3,146,157 shares issued at June 30, 2024 (unaudited) and December 31, 2023, respectively; 8,151,172 and 3,146,076 shares outstanding at June 30, 2024 (unaudited) and December 31, 2023, respectively   815    315 
Additional paid-in capital   128,448,699    121,233,901 
Accumulated deficit   (126,641,646)   (121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)   1,807,868    (322,858)
Noncontrolling interests in stockholders’ deficit   (328,483)   (328,409)
Total stockholders’ equity (deficit)   1,479,385    (651,267)
Total liabilities and stockholders’ equity (deficit)  $2,795,620   $2,708,085 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 1 
 

 

Ensysce Biosciences, Inc.

Consolidated Statements of Operations

(Unaudited)

 

                 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Federal grants  $181,797   $490,472   $487,519   $1,280,107 
Operating expenses:                    
Research and development   947,229    1,643,726    1,726,133    3,439,742 
General and administrative   1,190,010    1,140,700    2,559,791    2,695,553 
Total operating expenses   2,137,239    2,784,426    4,285,924    6,135,295 
                     
Loss from operations   (1,955,442)   (2,293,954)   (3,798,405)   (4,855,188)
Other income (expense):                    
Change in fair value of convertible notes   -    -    -    146,479 
Change in fair value of liability classified warrants   7,818    43,622    16,773    262,650 
Interest expense, net   (27,563)   -    (1,275,628)   (1,497)
Other income, net   7,394    11,030    (27,096)   16,448 
Total other income (expense), net   (12,351)   54,652    (1,285,951)   424,080 
                     
Net loss  $(1,967,793)  $(2,239,302)  $(5,084,356)  $(4,431,108)
Net loss attributable to noncontrolling interests   -    (7,060)   (74)   (11,001)
Deemed dividend related to warrants down round provision   -    3,729    290    12,038 
Net loss attributable to common stockholders  $(1,967,793)  $(2,235,971)  $(5,084,572)  $(4,432,145)
Net loss per basic and diluted share:                    
Net loss per share attributable to common stockholders, basic and diluted  $(0.22)  $(0.98)  $(0.67)  $(2.66)
Weighted average common shares outstanding, basic and diluted   8,817,316    2,274,113    7,640,192    1,667,527 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 2 
 

 

Ensysce Biosciences, Inc.

Consolidated Statements of Changes in Stockholders’ EQUITY (Deficit)

(Unaudited)

 

                          
   Stockholders’ Equity (Deficit) 
   Common Stock   Additional             
   Number of
Shares		   Amount   Paid-In
Capital		   Accumulated
Deficit		   Noncontrolling
interests		   Total 
Balance on March 31, 2023   1,284,583   $128   $113,293,834   $(113,127,237)  $(319,149)  $(152,424)
Settlement of restricted stock units   312    -    -    -    -    - 
Public offering, net   1,084,000    109    6,360,843    -    -    6,360,952 
Transaction costs associated with public offering   -    -    (253,836)   -    -    (253,836)
Issuance of common stock upon exercise of warrants   300,897    30    (30)   -    -    - 
Stock-based compensation   -    -    77,417    -    -    77,417 
Deemed dividend related to warrants down round provision   -    -    3,729    (3,729)   -    - 
Net loss   -    -         (2,232,242)   (7,060)   (2,239,302)
Balance on June 30, 2023   2,669,792   $267   $119,481,957   $(115,363,208)  $(326,209)  $3,792,807 
                               
Balance on March 31, 2024   7,329,172   $733   $128,422,232   $(124,673,853)  $(328,483)  $3,420,629 
Issuance of common stock upon warrant inducement   822,000    82    (82)   -    -    - 
Stock-based compensation   -    -    26,549    -    -    26,549 
Net Loss   -    -    -    (1,967,793)   -    (1,967,793)
Balance on June 30, 2024   8,151,172   $815   $128,448,699   $(126,641,646)  $(328,483)  $1,479,385 
                               
Balance on December 31, 2022   534,490   $53   $107,216,566   $(110,931,063)  $(315,208)  $(4,029,652)
Settlement of restricted stock units   624    -    -    -    -    - 
Settlement of commitment fee   44,444    4    399,996    -    -    400,000 
Conversion of convertible notes   408,580    41    3,056,851    -    -    3,056,892 
Public offerings, net   1,381,619    139    9,049,865    -    -    9,050,004 
Transaction costs associated with public offerings   -    -    (447,879)   -    -    (447,879)
Issuance of common stock upon exercise of warrants   300,897    30    (30)   -    -    - 
Stock-based compensation   -    -    194,550         -    194,550 
Reverse split fractional shares   (862)   -    -    -    -    - 
Deemed dividend related to warrants down round provision   -    -    12,038    (12,038)   -    - 
Net loss   -    -    -    (4,420,107)   (11,001)   (4,431,108)
Balance on June 30, 2023   2,669,792   $267   $119,481,957   $(115,363,208)  $(326,209)  $3,792,807 
                               
Balance on December 31, 2023   3,146,076   $315   $121,233,901   $(121,557,074)  $(328,409)  $(651,267)
Settlement of restricted stock units   63    -    -    -    -    - 
Conversion of convertible notes   745,521    75    1,168,525    -    -    1,168,600 
Issuance of common stock upon exercise of warrants   1,323,904    132    2,075,087    -    -    2,075,219 
Issuance of common stock upon warrant inducement, net of issuance costs   2,935,608    293    4,718,002    -    -    4,718,295 
Transaction costs associated with warrant inducement   -    -    (806,862)   -    -    (806,862)
Stock-based compensation   -    -    59,756    -    -    59,756 
Deemed dividend related to warrants down round provision   -    -    290    (290)   -    - 
Net loss   -    -    -    (5,084,282)   (74)   (5,084,356)
Balance on June 30, 2024   8,151,172   $815   $128,448,699   $(126,641,646)  $(328,483)  $1,479,385 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 3 
 

 

Ensysce Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

         
   Six Months Ended June 30, 
   2024   2023 
Cash flows from operating activities:          
Net loss  $(5,084,356)  $(4,431,108)
Adjustments to reconcile net loss to net cash used in operating activities:          
Accrued interest and interest expense related to note conversions   29,113    1,497 
Amortization of original issue discount and debt issuance costs   1,197,200    - 
Change in fair value of convertible notes   -    (146,479)
Change in fair value of liability classified warrants   (16,773)   (262,650)
Stock-based compensation   59,756    194,550 
Lease cost   -    (90)
Changes in operating assets and liabilities:          
Unbilled receivable   (126,662)   169,243 
Prepaid expenses and other assets   190,909    469,404 
Accounts payable   (1,795,404)   (1,669,162)
Accrued expenses and other liabilities   (172,077)   (1,040,666)
Net cash used in operating activities   (5,718,294)   (6,715,461)
Cash flows from financing activities:          
Proceeds public offering, net   -    9,050,004 
Proceeds from warrant exercises   2,075,219    - 
Proceeds from warrant inducement, net of issuance costs   4,718,295    - 
Transaction costs associated with public offering   -    (447,879)
Transaction costs associated with warrant inducement   (465,494)   - 
Repayment of convertible notes   (485,190)   (1,000,208)
Repayment of financed insurance premiums   (204,909)   (204,676)
Net cash provided by financing activities   5,637,921    7,397,241 
Increase (decrease) in cash and cash equivalents   (80,373)   681,780 
Cash and cash equivalents beginning of period   1,123,604    3,147,702 
Cash and cash equivalents end of period  $1,043,231   $3,829,482 
           
Supplemental disclosure of non-cash investing and financing activities:          
Incremental fair value of February 2024 warrant inducement  $5,167,372   $-  
Conversions of convertible notes into common stock  $1,168,600   $3,056,892 
Transaction costs from warrant inducement  $341,368   $- 
Deemed dividend related to warrants down round provision  $290   $12,038 
Financed insurance premiums  $235,155   $445,737 
Settlement of commitment fee in shares  $-   $400,000 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 4 
 

 

ENSYSCE BIOSCIENCES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Ensysce Biosciences, Inc. (“Ensysce”), along with its 79.2%-owned subsidiary, EBIR, Inc. (“EBIR”, formerly known as Covistat, Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is its program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR® (Multi-Pill Abuse Resistant) technology for overdose protection which will be applied to the PF614 program. The Company is also applying its TAAP and MPAR® technology to a methadone prodrug for use in the treatment of Opioid Use Disorder.

 

In 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the certificate of incorporation, EBIR was authorized to issue 1,000,000 shares of common stock, $0.001 par value per share, and 100,000 shares of preferred stock, $0.001 par value per share. Ensysce is a 79.2% stockholder in EBIR, with 9.9% and 10.9% of the shares held by a certain key person of the Company and two unrelated parties, respectively. The non-Ensysce owned shares and the activity are reflected on the financial statements as Noncontrolling interests.

 

The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

 

NOTE 2 - BASIS OF PRESENTATION

 

The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.

 

In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2023, which may be found in the Company’s Form 10-K filed with the SEC on March 15, 2024.

 

Going concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.

 

The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

 5 
 

 

While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.

 

The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of estimates and assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.

 

Cash and cash equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as two research and development vendors made up greater than 10% individually, and 31% and 38% in aggregate, of the outstanding accounts payable balance as of June 30, 2024 and December 31, 2023, respectively.

 

Property and equipment

 

Property and equipment are fully depreciated and as such there is no depreciation expense recognized in the periods presented.

 

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Pursuant to ASC 820, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of June 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

 6 
 

 

Warrants

 

The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants.

 

The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023.

 

   Total   Level 1   Level 2   Level 3 
   June 30, 2024 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants  $9,615   $      -   $       -   $9,615 
Total  $9,615   $-   $-   $9,615 

 

   Total   Level 1   Level 2   Level 3 
   December 31, 2023 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants   26,388          -           -    26,388 
Total  $26,388   $-   $-   $26,388 

 

The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024):

   Liability
classified
warrants		 
Fair value, December 31, 2023  $26,388 
Change in fair value   (16,773)
Fair value, June 30, 2024  $9,615 

 

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR® overdose prevention technology (the “MPAR Grant”). The initial grant was extended several times and cumulative funding under this grant of approximately $10.7 million was completed in December 2023.

 

 7 
 

 

In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $5.4 million and the current grant period ends August 31, 2024. As of June 30, 2024, the remaining cash funding under the grant is $1.9 million.

 

The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
MPAR  $-   $437,263   $-   $918,542 
TAAP/OUD   181,797    53,209    487,519    361,565 
Total  $181,797   $490,472   $487,519   $1,280,107 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded.

 

Research and development costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 

General and administrative expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 

Stock-based compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.

 

 8 
 

 

Income taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 

Net loss per share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period.

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below):

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Stock options   580,188    26,354    580,188    26,354 
RSUs   -    377    -    377 
Warrants   11,005,004    3,017,026    10,373,633    1,938,542 
Convertible notes   137,799    -    137,799    - 
Total   11,722,991    3,043,757    11,091,620    1,965,273 

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company.

 

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 

 9 
 

 

NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following:

   June 30,
2024		   December 31,
2023		 
Prepaid research and development  $539,208   $535,474 
Prepaid insurance   418,215    441,871 
Other prepaid expenses   170,439    72,358 
Other current assets   64,421    18,000 
Total prepaid expenses and other current assets  $1,192,283   $1,067,703 

 

NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consisted of the following:

   June 30,
2024		   December 31,
2023		 
Accrued research and development  $208,992   $329,228 
Professional fees   26,950    110,202 
Other accrued liabilities   134,244    102,830 
Total accrued expenses and other liabilities  $370,186   $542,260 

 

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of June 30, 2024, the Company’s commitments included approximately $16 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services.

 

Litigation

 

As of June 30, 2024, and December 31, 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

 

 10 
 

 

Lease

 

The Company’s current lease agreement (as amended) has a term that extends through October 31, 2024, with no contracted option to renew. As of June 30, 2024, the future lease payments totaled $11,363. The Company recognized total rent expense of $8,747 and $17,495 in the three and six months ended June 30, 2024 and $8,375 and $16,749 in the three and six-months ended June 30, 2023.

 

Share Subscription Facility

 

In December 2020, the Company executed the GEM Agreement, under which an investor agreed to provide the Company with a share subscription facility of up to $60.0 million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. Concurrent with the public listing of the Company’s shares on July 2, 2021, the Company issued to the investor 4,608 warrants with a three-year term to purchase common stock of Ensysce at an exercise price of $2,402.40 per share, subsequently reduced to $1.06 at February 12, 2024 (Note 8). Usage of the GEM facility is limited by other agreements of the Company. The Company has not raised any capital to date pursuant to the GEM facility.

 

NOTE 7 – NOTES PAYABLE

 

The following table provides a summary of the Company’s outstanding debt as of June 30, 2024:

   Principal
balance		   Accrued
interest		   Net debt
balance		 
2023 Notes  $216,000    6,308 -  222,308 
Financed insurance   232,155    - -  232,155 
Total  $448,155   $6,308 - $454,463 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2023:

 

   December 31, 2023 
   Principal
balance		   Accrued
interest		   Unamortized Debt
Discount and
Issuance Costs		   Net debt
balance		 
2023 Notes  $1,836,000   $13,078   $(1,197,200)  $651,878 
Financed insurance   197,249    5,570    -    202,819 
Total  $2,033,249   $18,648   $(1,197,200)  $854,697 

 

 11 
 

 

Interest Expense

 

The interest expense recognized for financed insurance was $148 and $2,092 for the three and six months ended June 30, 2024 and $0 and $1,497 for the three and six months ended June 30, 2023. Interest expense recognized for the 2023 Notes was $27,563 and $1.3 million for the three and six months ended June 30, 2024, which consists of amortization of the debt discount and debt issuance costs and incurred and accrued interest.

 

2023 Notes

 

On October 23, 2023, the Company entered into a Securities Purchase Agreement (“SPA”) for an aggregate financing of $1.8 million with investors, including $0.2 million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $612,000 for an aggregate purchase price of $566,667 and (ii) warrants to purchase 1,255,697 shares of the Company’s common stock, par value $0.0001 per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors referenced above, (i) additional notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333 and (ii) additional warrants to purchase 2,511,394 shares of the common stock in the aggregate. The notes were scheduled to mature on April 25, 2024 and May 28, 2024, respectively.

 

The combined notes are subject to an original issue discount of 8%, have an original term of six months from their respective date of issuance and accrue interest at the rate of 6.0% per annum. The notes are convertible into common stock, at a per share conversion price equal to $1.5675. Beginning ninety days following issuance of the respective notes, the Company was obligated to redeem monthly one third of the original principal amount under the applicable note, plus accrued but unpaid interest, liquidated damages and any other amounts then owing to the holder of such note. The Company is required to pay the redemption amount in cash with a premium of 10% or, at the election of the purchaser at any time, some or all of the principal amount and interest may be paid by conversion of shares under the note into common stock based on a conversion price equal to $1.5675. The Company determined the 2023 Notes are to be accounted for as conventional convertible debt as they provide for the holder an option to convert the outstanding balances into a fixed number of shares (or an equivalent amount of cash at the discretion of the Company) and the option to convert meets the definition of an exception from derivative accounting. As a result, the Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of the balance sheet. The amortization of the original debt discount (approximately $0.1 million) and issuance costs (approximately $0.3 million) was recorded as interest expense within the consolidated statements of operations. As of June 30, 2024, the original debt discount and issuance costs were fully amortized to interest expense.

 

The warrants have an exercise price of $1.5675, the same as the conversion price, and are exercisable for five years following the issuance date. The warrants were equity classified as they are indexed to the Company’s stock and only settleable in shares. The warrants were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative fair value method. The initial fair value of $1.1 million allocated to the warrants was considered a debt discount and will be amortized to interest expense over the remaining term of the notes. As of June 30, 2024, the discount associated with the warrants was fully amortized to interest expense.

 

 12 
 

 

During 2024, the Company converted 745,521 shares of common stock with a conversion value of $1.2 million related to the 2023 Notes. In addition, in connection with the SPA, the Company incurred a $1.0 million waiver fee in connection to the 2024 Warrant Inducement (see Note 8) to pay down $0.5 million of 2023 Notes and $0.5 million in transaction costs recorded as such in the consolidated statement of stockholders’ equity. As of June 30, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible promissory notes held with a Company board member (see Note 10).

 

Financed insurance premiums

 

In June 2024, the Company renewed and financed its directors’ and officers’ liability insurance in the amount of $0.2 million. Monthly payments are scheduled from July 2024 through March 2025.

 

NOTE 8 - STOCKHOLDERS’ EQUITY

 

The Company’s current Certificate of Incorporation authorizes 250,000,000 shares of common stock and 1,500,000 shares of preferred stock, both with par value equal to $0.0001. As of June 30, 2024, and December 31, 2023, there were no shares of preferred stock issued and outstanding.

 

2024 Warrant Inducement

 

On February 12, 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of 3,601,752 shares of Common Stock at a reduced exercise price of $1.31 per share in consideration of the Company’s agreement to issue new unregistered Series A Warrants (the “Series A Warrants”) to purchase up to 3,601,752 shares of Common Stock and new unregistered Series B Warrants (the “Series B Warrants”) to purchase up to 3,601,752 shares of Common Stock (collectively, the “New Warrant Shares”). The Series A Warrants have an exercise price of $1.06 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an exercise price of $1.06 per share and will expire on May 12, 2028. The gross proceeds to the Company from the exercise of the warrants were approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses. As the existing warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $5.2 million as an equity issuance cost.

 

In connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes’ SPA it had entered as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note 7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant inducement.

 

The Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $0.3 million in legal fees and other closing costs. Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement agent warrants expire on May 12, 2028, and have an exercise price of $1.6375 per share of Common Stock (equal to 125% of the reduced exercise price per Existing Warrant).

 

The closing of the offering occurred on February 14, 2024.

 

 13 
 

 

Abeyance Shares

 

Related to the 2024 Warrant Inducement, a holder left 1,488,144 shares in abeyance at the Company’s transfer agent to be delivered to the holder at their request. During the quarter ended June 30, 2024, 822,000 shares held in abeyance were delivered to the holder and the remaining shares are held in abeyance. Accordingly, as of June 30, 2024, 666,144 shares were held in abeyance, have not been issued and are not outstanding.

 

Warrants

 

The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2024:

Reference  Shares
Underlying
Outstanding
Warrants		   Exercise
Price		   Description  Classification
(a)   63,659   $2,400.00 - 2,760.00   LACQ warrants  Equity
(b)   4,608   $1.31   Share subscription facility  Equity
(c)   4,518   $3.64   2021 Notes  Liability
(d)   38,900   $3.64   2022 Notes  Liability
(e)   549,993   $3.64 - 16.80   Public offering  Equity
(f)   318,451   $8.58 - 12.60   Public offering  Equity
(g)   126,061   $4.86   Public offering  Equity
(h)   2,443,187   $1.57   2023 Notes  Equity
(i)   7,455,627   $1.06 - 1.64   2024 Warrants  Equity
    11,005,004            

 

(a) On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 warrants previously issued by LACQ (subsequently in December 2022 and August 2023, 7,782 and 7,310 warrants, respectively, were cancelled). The warrants provide holders the right to purchase common stock at a strike price of between $2,400.00 and $2,760.00 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 41,666 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 21,993 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 warrants issued on June 30, 2021 from $2,760.00 to $2,400.00 per share.
   
(b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an initial exercise price of $2,402.40 per share. The warrants have been subject to multiple exercise price reductions as required by a down-round adjustment feature of the warrant, due to common stock issued at prices below the then current exercise price. The adjustments have progressed from the original exercise price of $2,402.40 per share to the current exercise price at June 30, 2024 of $1.06 per share. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a Black-Scholes model) is reflected on the consolidated statement of operations as a deemed dividend.

 

 14 
 

 

(c) On September 24, 2021 and November 5, 2021, the Company issued 1,507 and 3,011 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $1,831.20 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026 and November 4, 2026, respectively. As a result of the issuance of the 2022 Notes in July 2022, the exercise price of these warrants was adjusted down to $187.20. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(d) On July 1, 2022 and August 9, 2022, the Company issued 19,450 warrants each in connection with the issuance of the 2022 Notes. The warrants were immediately exercisable with an exercise price of $170.04 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on June 29, 2027 and August 8, 2027, respectively. As a result of the issuance of shares and warrants in connection with the December 2022 public offering, the exercise price of these warrants was adjusted down to $24.07. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(e) On December 9, 2022, the Company issued 549,993 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $16.80 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on December 9, 2027. On May 12, 2023, in exchange for $0.125 per applicable warrant, the Company amended 166,667 of these warrants to reduce their exercise price to $3.64.
   
(f) On February 6, 2023, the Company issued 318,451 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $8.58 - $12.60 and expire on February 2, 2028, and August 7, 2028.
   
(g) On May 12, 2023, the Company issued 3,727,813 equity classified warrants (Series A-1, A-2, and placement agent warrants) in connection with a public offering. The warrants were immediately exercisable with an exercise price of $3.64 - $4.86 and expire on November 12, 2024, May 10, 2028, and May 12, 2028. In connection to the Inducement Letter entered into February 12, 2024, certain existing warrant holders agreed to exercise 3,601,752 Series A-1 and A-2 warrants at a reduced exercise price of $1.31. The placement agent warrants remain outstanding as of June 30, 2024.
   
(h)

On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 shares and 2,511,394 shares, respectively. The warrants were immediately exercisable with an exercise price of $1.5675 and expire on October 25, 2028 and November 28, 2028, respectively. In January 2024, a holder of the warrants exercised 1,323,904 warrants at an exercise price of $1.5675.

 

(i) On February 12, 2024, the Company issued 7,455,627 equity classified warrants (Series A Warrants, Series B Warrants and placement agent warrants) in connection with the Inducement Letter for the 2024 warrant inducement and related warrant restructuring. The Series A and Series B Warrants were immediately exercisable with an exercise price of $1.06 and expire on August 14, 2025 and May 12, 2028, respectively. The placement agent warrants were immediately exercisable with an exercise price of $1.6375 and expire on May 12, 2028.

 

 15 
 

 

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

   Stock price   Exercise price   Expected term (years)   Volatility   Risk free rate 
(a) LACQ warrants (grant date varies)  $3,477.60   $2,400.00 - $2,760.00     3.00    110.0%   0.5%
(b) Share subscription facility (grant date 7/2/21)  $3,477.60   $2,402.40    3.00    110.0%   0.5%
(b) Share subscription facility (remeasurement date varies)  $1.13 - $1,029.60    $1.06- $680.23     0.38 - 2.58    91.3% - 140.5%    1.04% - 5.43% 
(c) Liability classified warrants (grant date 9/24/21)  $1,077.60   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (grant date 11/5/21)  $540   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    2.25 - 2.35    133.7% - 135.4%    4.6%
(d) Liability classified warrants (grant date 7/1/22)  $136.80   $170.04    5.00    98.9%   2.9%
(d) Liability classified warrants (grant date 8/9/22)  $127.20   $170.04    5.00    102.8%   3.0%
(d) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    3.00 - 3.11    126.7% - 128.6%    4.4%

 

NOTE 9 - STOCK-BASED COMPENSATION

 

In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2023, the Company’s Board approved an annual increase of 26,725 shares and in August 2023, the Company’s stockholders approved a proposal for an increase of 585,796 shares available for future grant under the 2021 Omnibus Plan.

 

The Company recognized stock-based compensation expense within general and administrative expense of $18,658 and $42,146 for the three and six months ended June 30, 2024 and $60,394 and $156,663 for the three and six months ended June 30, 2023. The Company recognized stock-based compensation expense within research and development expense of $7,891 and $17,610 for the three and six months ended June 30, 2024 and $17,023 and $37,887 for the three and six months ended June 30, 2023.

 

Option Activity

 

There were no stock options granted during the six months ended June 30, 2024 and June 30, 2023.

 

The following table summarizes the Company’s stock option activity during the six months ended June 30, 2024:

       Weighted average     
   Options   Exercise price   Remaining contractual life   Intrinsic value 
Outstanding at December 31, 2023   581,314   $33.15    9.57   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired / Forfeited   -    -    -    - 
Outstanding at June 30, 2024   581,314    33.15    9.08    - 
Exercisable at June 30, 2024   580,188    32.28    -    - 
Vested and expected to vest   581,314    33.15    9.08    - 

 

16

 

 

Option Valuation

 

The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in during the six months ended June 30, 2024 and 2023):

 

  ● Expected stock-price volatility. The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
  ● Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
  ● Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
  ● Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.

 

As of June 30, 2024, the Company had an aggregate of $60,092 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 0.95 years.

 

Shares Reserved for Future Issuance

 

The following shares of common stock are reserved for future issuance:

   June 30, 2024 
Awards outstanding under the 2021 Omnibus Incentive Plan   581,314 
Awards available for future grant under 2021 Omnibus Incentive Plan   2,112 
Warrants outstanding   11,005,004 
Total shares of common stock reserved for future issuance   11,588,430 

 

NOTE 10 - RELATED PARTIES

 

As of June 30, 2024, the Company held a $0.2 million senior secured convertible promissory note plus accrued interest and 0.4 million warrants exercisable for common stock at $1.5675 per share issued from a board member in connection to the issuance of the 2023 Notes. On April 25, 2024, the Company and the board member entered into a forbearance agreement that will expire on April 25, 2025. Upon termination of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company may pay the notes in full at any time prior to the conclusion of the forbearance period.

 

17

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and notes thereto included elsewhere in this report. In addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section within Part II-Other Information - titled “Item 1A. Risk Factors.”

 

References in the following discussion to “we”, “us”, “our” and the “Company” refer to Ensysce Biosciences, Inc. and its consolidated subsidiaries following the Closing of the Business Combination. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing.

 

Overview

 

Ensysce is a clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our lead product candidate, PF614, is an extended release TAAP prodrug of oxycodone. TAAP modification of prescription drugs removed the ability to crush, chew or manipulate and inject to achieve the effect of the medication more quickly than by swallowing. MPAR® adds a layer of overdose protection to each TAAP product.

 

Since our inception in 2003, we devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our product candidates. We do not have any products approved for sale and we have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product.

 

Our lead product candidate, PF614, is ready for Phase 3 clinical development, PF614-MPAR is in Phase 1b clinical development and nafamostat has completed Phase 1 clinical development. Our other product candidates and our research initiatives are in preclinical or earlier stages of development. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. We have not yet successfully completed any pivotal clinical trials, nor have we obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.

 

We have incurred significant operating losses since inception and we expect to continue to incur net losses for the foreseeable future. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing development activities, particularly if and as we:

 

  ● continue preclinical studies and continues existing and initiates new clinical trials for PF614, PF614-MPAR and nafamostat, our lead product candidates being tested for chronic pain and infectious disease;
     
  ● advance the development of our product candidate pipeline of other product candidates, including through business development efforts to invest in or in-license other technologies or product candidates;
     
  ● maintain, expand and protect our intellectual property portfolio;
     
  ● hire additional clinical, quality control, medical, scientific and other technical personnel to support our clinical operations;
     
  ● seek regulatory approval for any product candidates that successfully complete clinical trials;
     
  ● undertake any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval;
     
  ● expand our infrastructure and facilities to accommodate our growing employee base; and
     
  ● add operational, financial and management information systems and personnel, including personnel to support our research and development programs and any future commercialization efforts.

 

18

 

 

We have incurred and expect to continue to incur costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses. We may never become profitable.

 

We require substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of private and public equity offerings, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, existing ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our equity holders.

 

Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations or other strategic transactions with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.

 

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

 

We have generated limited revenues, have incurred significant operating losses since our inception and expect to continue to incur operating losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern. Our future viability is dependent on our ability to raise additional capital to finance our operations.

 

We expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing, or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding in the future.

 

2024 Warrant Inducement

 

On February 12, 2024, the Company entered into an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of 3,601,752 shares of Common Stock at a reduced exercise price of $1.31 per share in consideration of the Company’s agreement to issue new unregistered Series A Warrants (the “Series A Warrants”) to purchase up to 3,601,752 shares of Common Stock and new unregistered Series B Warrants (the “Series B Warrants”) to purchase up to 3,601,752 shares of Common Stock (collectively, the “New Warrant Shares”). The Series A Warrants have an exercise price of $1.06 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an exercise price of $1.06 per share and will expire on May 12, 2028. The gross proceeds to the Company from the exercise of the warrants were approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering occurred on February 14, 2024.

 

In connection with the execution of the Inducement Letter, the Company entered into a waiver related to the 2023 Notes’ SPA it had entered into as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included entering into the Inducement Letter. The Waiver permitted the Company to enter into the Inducement Letter but required repayment of the remaining $0.5 million of investor held notes issued under the SPA with a premium of $0.5 million following closing of the transaction contemplated thereby.

 

19

 

 

The Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $0.5 million in legal fees and other closing costs. Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement agent warrants expire on May 12, 2028, and have an exercise price of $1.6375 per share of Common Stock (equal to 125% of the reduced exercise price per Existing Warrant).

 

Components of Our Operating Results

 

Revenue

 

We have generated limited revenue since our inception and we do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts are successful and we commercialize our products, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, as well as upfront, milestone and royalty payments from such collaboration or license agreements, or a combination thereof.

 

We have received funding under federal grants from the NIH through NIDA. In September 2018, we were awarded a research and development grant related to the development of our MPAR® overdose prevention technology (the “MPAR Grant”). In September 2019, we were awarded a second research and development grant related to the development of our TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (“OUD”) (the “OUD Grant”). Grant funds are awarded annually through a Notice of Award which contains certain terms and conditions including, but not limited to, complying with the grant program legislation, regulation and policy requirements, complying with conditions on expenditures of funds with respect to other applicable statutory requirements such as the federal appropriations acts, periodic reporting requirements, and budget requirements.

 

Operating Expenses

 

Research and Development Expenses

 

Research and development expenses consist primarily of costs incurred for research activities, including drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:

 

  ● expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
     
  ● expenses incurred under agreements with CROs that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and CMOs that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;
     
  ● other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
     
  ● payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
     
  ● employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
     
  ● costs related to compliance with regulatory requirements; and
     
  ● allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.

 

20

 

 

We recognize external development costs as incurred. Any advance payments we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. We estimate and accrue for the value of goods and services received from CROs and certain other third parties each reporting period based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs.

 

We do not track our research and development expenses on a program-by-program basis. Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to manage our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by program and cannot state precisely the total costs incurred for each of our clinical and preclinical programs on a project-by-project basis.

 

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will remain elevated as we continue our existing, and commence additional, planned clinical trials for PF614, PF614-MPAR and nafamostat, as well as conduct other preclinical and clinical development, including submitting regulatory filings for our other product candidates, subject to our ability to obtain financing. We also expect our related personnel costs to increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, to remain elevated. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter license, acquisition and option agreements to acquire the rights to future product candidates.

 

At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates are highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:

 

  ● the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;
     
  ● establishing an appropriate safety and efficacy profile with investigational new drug (“IND”) enabling studies;
     
  ● successful patient enrollment in and the initiation and completion of clinical trials;
     
  ● the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;
     
  ● the extent of any required post-marketing approval commitments to applicable regulatory authorities;
     
  ● establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;

 

21

 

 

  ● development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
     
  ● obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
     
  ● significant and changing government regulation;
     
  ● launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
     
  ● maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.

 

Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of employee-related expenses, including salaries and related benefits, travel and stock-based compensation for personnel in executive, business development, finance, human resources, legal, information technology, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expense general and administrative costs as incurred.

 

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the continued development of our product candidates, subject to our ability to obtain financing. We also anticipate that we will continue to incur significant accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.

 

Other Income (Expense)

 

Change in fair value of convertible notes

 

The 2022 Notes were accounted for under ASC 480 – Distinguishing Liabilities from Equity, due to share settlement features contained within the notes. We used a discounted cash flow model and a Monte Carlo simulation to estimate the fair value of the notes, both of which rely on unobservable Level 3 inputs. Changes in the fair value of the notes are recognized through earnings for each reporting period.

 

22

 

 

Change in fair value of liability classified warrants

 

We use a Black-Scholes option pricing model to estimate the fair value of the liability classified warrants. Changes in the fair value of the warrants are recognized through earnings for each reporting period.

 

Interest Expense

 

Interest expense consists of interest accrued on our financed directors’ and officers’ insurance, and accumulated interest from the 2023 Notes based on the stated interest rate. In addition, the 2023 Notes balances reflect amortization of the debt discount from the original issuance and a discount associated with the warrant issuances and amortization of the associated debt issuance costs that are all recorded as interest expense. Interest expense related to the 2021 Notes and 2022 Notes was included in the estimate of fair value of the convertible notes.

 

Provision for Income Taxes

 

We have not recorded any significant amounts related to income tax expense, we have not recognized any reserves related to uncertain tax positions, nor have we recorded any income tax benefits for the majority of our net losses we have incurred to date or for our research and development tax credits.

 

We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or our tax returns. Deferred tax assets and liabilities are determined based on difference between the financial statement carrying amounts and tax bases of existing assets and liabilities and for loss and credit carryforwards, which are measured using the enacted tax rates and laws in effect in the years in which the differences are expected to reverse. The realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2024 and December 31, 2023, we continue to maintain a full valuation allowance against all of our deferred tax assets based on our evaluation of all available evidence.

 

Beginning in 2022, the Tax Cuts and Jobs Act, or the Tax Act, eliminated the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Internal Revenue Code Section 174. This has not impacted our effective tax rate or our cash tax payable in 2024; however, if the requirement to capitalize Section 174 expenditures is not modified, it may also impact our effective tax rate and our cash tax liability in future years.

 

We file income tax returns in the United States federal tax jurisdiction and state jurisdictions and may become subject to income tax audit and adjustments by related tax authorities. Our tax return period for United States federal income taxes for the tax years since 2020 remain open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions. We record reserves for potential tax payments to various tax authorities related to uncertain tax positions, if any. The nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial. These reserves are based on a determination of whether and how much a tax benefit taken by us in our tax filings or whether our position is more likely than not to be realized following the resolution of any potential contingencies related to the tax benefit. We develop our assessment of uncertain tax positions, and the associated cumulative probabilities, using internal expertise and assistance from third-party experts. As additional information becomes available, estimates are revised and refined. Differences between estimates and final settlement may occur resulting in additional tax expense. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of our provision for income taxes. To date, no amounts are being presented as an uncertain tax position.

 

23

 

 

Results of Operations

 

Comparison of the three months ended June 30, 2024 and 2023:

 

   Three Months Ended June 30,     
   2024   2023   Change 
Federal grants  $181,797   $490,472   $(308,675)
Operating expenses:               
Research and development   947,229    1,643,726    (696,497)
General and administrative   1,190,010    1,140,700    49,310 
Total operating expenses   2,137,239    2,784,426    (647,187)
Loss from operations   (1,955,442)   (2,293,954)   338,512 
Other income (expense):               
Change in fair value of liability classified warrants   7,818    43,622    (35,804)
Interest expense   (27,563)    -    (27,563)
Other income, net   7,394    11,030    (3,636)
Total other income (expenses), net   (12,351)   54,652    (67,003)
Net loss   (1,967,793)   (2,239,302)   271,509 
Net loss attributable to noncontrolling interests   -    (7,060)   7,060 
Deemed dividend related to warrants down round provision   -    3,729    (3,729)
Net loss attributable to common stockholders  $(1,967,793)  $(2,235,971)  $268,178 

 

Federal grant funding

 

Funding from federal grants for the three months ended June 30, 2024 and 2023 totaled $0.2 million and $0.5 million, respectively. The difference is due to the timing of research activities eligible for funding, as current funding under the MPAR grant was completed in December 2023. We expect funding from federal grants to increase in the third quarter due to increased preclinical activities under the OUD grant following the recent selection of a lead drug candidate.

 

Research and development expenses

 

Research and development expenses for the three months ended June 30, 2024 and 2023 were $0.9 million and $1.6 million, respectively, representing a decrease of $0.7 million. The decrease was primarily the result of reduced external research and development costs related to clinical and pre-clinical programs for PF614 and PF614-MPAR. We do not currently track expenses on a program-by-program basis. We expect future research and development expenses to approximate current levels but may need to adjust the timing of research and development based on our ability to raise capital sufficient to fund these expenses.

 

General and administrative expenses

 

General and administrative expenses for the three months ended June 30, 2024 and 2023 were $1.2 million and $1.1 million, respectively, representing an increase of $0.1 million. We expect future general and administrative expenses to approximate current levels.

 

Other income and expense

 

Other income and expense for the three months ended June 30, 2024, consisted primarily of interest expenses associated with the amortization of the original issue discount and the debt issuance costs associated with the 2023 Notes. The comparative period for 2023 consisted primarily of changes in fair value associated with the Company’s liability-classified warrants.

 

24

 

 

Results of Operations

 

Comparison of the six months ended June 30, 2024 and 2023:

 

   Six Months Ended June 30     
   2024   2023   Change 
Federal grants  $487,519   $1,280,107   $(792,588)
Operating expenses:               
Research and development   1,726,133    3,439,742    (1,713,609)
General and administrative   2,559,791    2,695,553    (135,762)
Total operating expenses   4,285,924    6,135,295    (1,849,371)
Loss from operations   (3,798,405)   (4,855,188)   1,056,783 
Other income (expense):               
Change in fair value of convertible notes   -    146,479    (146,479)
Change in fair value of liability classified warrants   16,773    262,650    (245,877)
Interest expense   (1,275,628)   (1,497)   (1,274,131)
Other income, net   (27,096)   16,448    (43,544)
Total other income, net   (1,285,951)   424,080    (1,710,031)
Net loss   (5,084,356)   (4,431,108)   (653,248)
Net loss attributable to noncontrolling interests   (74)   (11,001)   10,927 
Deemed dividend related to warrants down round provision   290    12,038    (11,748)
Net loss attributable to common stockholders  $(5,084,572)  $(4,432,145)  $(652,427)

 

Federal grant funding

 

Funding from federal grants for the six months ended June 30, 2024 and 2023 totaled $0.5 million and $1.3 million, respectively. The difference is due to the timing of research activities eligible for funding, as current funding under the MPAR grant was completed in December 2023. We expect funding from federal grants to increase in the second half of 2024 due to increased preclinical activities under the OUD grant following the recent selection of a lead drug candidate.

 

Research and development expenses

 

Research and development expenses for the six months ended June 30, 2024 and 2023 were $1.7 million and $3.4 million, respectively, representing a decrease of $1.7 million. The decrease was primarily the result of reduced external research and development costs related to clinical and pre-clinical programs for PF614 and PF614-MPAR. We do not currently track expenses on a program-by-program basis. We expect future research and development expenses to approximate current levels but may need to be adjusted based on our ability to raise capital sufficient to fund these expenses.

 

General and administrative expenses

 

General and administrative expenses for the six months ended June 30, 2024 and 2023 were $2.6 million and $2.7 million, respectively, representing a decrease of $0.1 million. We expect future general and administrative expenses to approximate current levels.

 

Other income and expense

 

Other income and expense for the six months ended June 30, 2024, consisted primarily of interest expense associated with the amortization of the original issue discount and the debt issuance costs associated with the 2023 Notes and represented a net change in other income and expense of $1.3 million compared to the six months ended June 30, 2023. The comparative period for 2023 consisted primarily of changes in fair value associated with the 2022 Notes and the Company’s liability-classified warrants.

 

25

 

 

Liquidity and capital resources

 

Sources of liquidity and capital

 

As of June 30, 2024, we had $1.0 million of cash and cash equivalents. Since inception, we have generated limited revenues and have incurred significant operating losses and negative cash flows from our operations, and we anticipate that we will continue to incur losses for the foreseeable future. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all.

 

We have funded our operations to date primarily with proceeds from the sale of common equity, funding under federal research grants and borrowings under convertible promissory notes. To fund future operations, we will need to raise additional capital. The amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing research and development efforts and related general and administrative support. We anticipate that we will fund our operations through public or private equity or debt financings or other sources, such as potential collaboration agreements. We cannot make assurances that anticipated additional financing will be available to us on favorable terms, if at all.

 

Remaining cash funding under two approved federal research grants totaled $1.9 million at June 30, 2024 and is expected to be utilized by August 31, 2024. Pursuant to the terms and conditions of the two grants, we are required to submit progress reports to NIDA on an annual basis and a final research performance progress report within 120 days of the performance period end date.

 

Going Concern

 

We have generated limited revenues and have incurred significant operating losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Without capital raised through financing transactions, existing cash resources are sufficient to allow us to fund current planned operations into the third quarter of 2024, which raises substantial doubt about the Company’s ability to continue as a going concern.

 

Cash flows

 

The following table summarizes our cash flows for each of the periods presented:

 

   Six Months Ended June 30, 
   2024   2023 
Net cash used in operating activities  $(5,718,294)  $(6,715,461)
Net cash provided by (used in) financing activities   5,637,921    7,397,241 
Net increase (decrease) in cash and cash equivalents  $(80,373)  $681,780 

 

Operating activities

 

During the six months ended June 30, 2024 and 2023, we used cash in operating activities of $5.7 million and $6.7 million, respectively. The decrease primarily resulted from the timing of vendor invoicing and payments and a reduction in research and development activities in the 2024 period.

 

Financing activities

 

During the six months ended June 30, 2024, net cash provided by financing activities was $5.6 million, primarily consisting of net proceeds from warrant exercises and the warrant inducement, less repayment of convertible notes and financed insurance premiums. During the six months ended June 30, 2023, net cash provided by financing activities was $7.4 million, primarily consisting of net proceeds from the 2023 February and 2023 May Offerings, less repayment of convertible notes and financed insurance premiums.

 

26

 

 

Funding requirements

 

Our primary use of cash is to fund operating expenses, primarily related to our research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.

 

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we have incurred, and will continue to incur, additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:

 

  ● advance preclinical development of our early-stage programs and clinical trials of our product candidates;
     
  ● manufacture, or have manufactured on our behalf, preclinical and clinical drug material and develop processes for late state and commercial manufacturing;
     
  ● seek regulatory approvals for any product candidates that successfully complete clinical trials;
     
  ● establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
     
  ● hire additional clinical, quality control and scientific personnel;
     
  ● expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
     
  ● obtain, maintain, expand and protect our intellectual property portfolio;
     
  ● manage the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and
     
  ● manage the costs of operating as a public company.

 

27

 

 

Commitments

 

Our commitments as of June 30, 2024, included approximately $16 million related to open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule, and adjust requirements based on our business needs prior to the delivery of goods or the performance of services.

 

Working capital

 

Because of the numerous risks and uncertainties associated with research, development and commercialization of biologic product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly because of many factors, including:

 

  ● the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;
     
  ● the costs, timing and outcome of regulatory review of our product candidates;
     
  ● the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;
     
  ● the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
     
  ● the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;
     
  ● the ability to receive additional non-dilutive funding, including grants from organizations and foundations;
     
  ● the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
     
  ● the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
     
  ● our ability to establish and maintain collaborations on favorable terms, if at all; and
     
  ● the extent to which we acquire or in-license other product candidates and technologies.

 

28

 

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are described in more detail in Note 3 to our audited consolidated financial statements included in our 2023 Annual Report on Form 10-K, we believe that the following accounting policy is the most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

 

Accrued Research and Development Expenses

 

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual costs. Many of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and adjust if necessary. Examples of estimated accrued research and development expenses include fees paid to:

 

  ● vendors, including research laboratories, in connection with preclinical development activities;
     
  ● CROs and investigative sites in connection with preclinical studies and clinical trials; and
     
  ● CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.

 

We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.

 

Off-Balance Sheet Arrangements

 

We do not have during the periods presented, and do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

 

Recently issued accounting pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact Ensysce’s financial position and results of operations is disclosed in Note 3 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Smaller reporting company status

 

We are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the prior June 30, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30.

 

29

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are exposed to market risk in the ordinary course of our business, primarily related to changes in interest rates and inflation.

 

Interest Rate Risk

 

Our cash and cash equivalents as of June 30, 2024, consisted of cash and a money market fund account. Because of the short-term nature of our money market fund, a sudden change in market interest rates would not be expected to have a material impact on our financial position or results of operations.

 

Inflation Risk

 

We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a–15(e) and 15d-15(e)) as of June 30, 2024. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2024. Management has concluded that our financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

30

 

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, we review the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation.

 

Item 1A. Risk Factors.

 

While we attempt to identify, manage and mitigate risks and uncertainties associated with our business to the extent practical, under the circumstances, some level of risk and uncertainty will always be present. Part I, Item 1A. Risk Factors of our 2023 Annual Report on Form 10-K includes a detailed discussion of our risk factors. Those risks and uncertainties have the potential to materially affect our financial condition and results of operations.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information

 

None.

 

31

 

 

Item 6. Exhibits.

 

The following exhibits are filed as part of this report:

 

Exhibit

Number

   Description
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

32

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ENSYSCE BIOSCIENCES, INC.
   
Date: August 14, 2024 /s/ David Humphrey
  David Humphrey
  Chief Financial Officer, Secretary and Treasurer

 

33

 

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lynn Kirkpatrick, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ensysce Biosciences, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2024    
    /s/ Lynn Kirkpatrick
  Name: Lynn Kirkpatrick
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Humphrey, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ensysce Biosciences, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2024    
    /s/ David Humphrey
  Name: David Humphrey
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 

Exhibit 32.1

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ensysce Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lynn Kirkpatrick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

 

Date: August 14, 2024 /s/ Lynn Kirkpatrick
  Lynn Kirkpatrick
  Chief Executive Officer
  (Principal Executive Officer)

 

This certification accompanies the Report and shall not be deemed “filed” by the Company with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ensysce Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Humphrey, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

 

Dated: August 14, 2024 /s/ David Humphrey
  David Humphrey
  Chief Financial Officer
  (Principal Financial Officer)

 

This certification accompanies the Report and shall not be deemed “filed” by the Company with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

 

 

 

v3.24.2.u1
Cover - $ / shares
 6 Months Ended
Jun. 30, 2024
Aug. 12, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2024  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38306  
Entity Registrant Name Ensysce Biosciences, Inc.  
Entity Central Index Key 0001716947  
Entity Tax Identification Number 82-2755287  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 7946 Ivanhoe Avenue  
Entity Address, Address Line Two Suite 201  
Entity Address, City or Town La Jolla  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92037  
City Area Code (858)  
Local Phone Number 263-4196  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ENSC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Bankruptcy Proceedings, Reporting Current true  
Entity Common Stock, Shares Outstanding   8,471,172
Entity Listing, Par Value Per Share $ 0.0001  
v3.24.2.u1
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 1,043,231 $ 1,123,604
Unbilled receivable 224,223 97,561
Prepaid expenses and other current assets 1,192,283 1,067,703
Total current assets 2,459,737 2,288,868
Other assets 335,883 419,217
Total assets 2,795,620 2,708,085
Current liabilities:    
Accounts payable 481,971 1,936,007
Accrued expenses and other liabilities 370,186 542,260
Notes payable and accrued interest 454,463 854,697
Total current liabilities 1,306,620 3,332,964
Long-term liabilities:    
Liability classified warrants 9,615 26,388
Total long-term liabilities 9,615 26,388
Total liabilities 1,316,235 3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2024 (unaudited) and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2024 (unaudited) and December 31, 2023; 8,151,253 and 3,146,157 shares issued at June 30, 2024 (unaudited) and December 31, 2023, respectively; 8,151,172 and 3,146,076 shares outstanding at June 30, 2024 (unaudited) and December 31, 2023, respectively 815 315
Additional paid-in capital 128,448,699 121,233,901
Accumulated deficit (126,641,646) (121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 1,807,868 (322,858)
Noncontrolling interests in stockholders’ deficit (328,483) (328,409)
Total stockholders’ equity (deficit) 1,479,385 (651,267)
Total liabilities and stockholders’ equity (deficit) $ 2,795,620 $ 2,708,085
v3.24.2.u1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 8,151,253 3,146,157
Common stock, shares outstanding 8,151,172 3,146,076
v3.24.2.u1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Federal grants $ 181,797 $ 490,472 $ 487,519 $ 1,280,107
Operating expenses:        
Research and development 947,229 1,643,726 1,726,133 3,439,742
General and administrative 1,190,010 1,140,700 2,559,791 2,695,553
Total operating expenses 2,137,239 2,784,426 4,285,924 6,135,295
Loss from operations (1,955,442) (2,293,954) (3,798,405) (4,855,188)
Other income (expense):        
Change in fair value of convertible notes 146,479
Change in fair value of liability classified warrants 7,818 43,622 16,773 262,650
Interest expense, net (27,563) (1,275,628) (1,497)
Other income, net 7,394 11,030 (27,096) 16,448
Total other income (expense), net (12,351) 54,652 (1,285,951) 424,080
Net loss (1,967,793) (2,239,302) (5,084,356) (4,431,108)
Net loss attributable to noncontrolling interests (7,060) (74) (11,001)
Deemed dividend related to warrants down round provision 3,729 290 12,038
Net loss attributable to common stockholders $ (1,967,793) $ (2,235,971) $ (5,084,572) $ (4,432,145)
Net loss per basic and diluted share:        
Net loss per share attributable to common stockholders, basic $ (0.22) $ (0.98) $ (0.67) $ (2.66)
Net loss per share attributable to common stockholders, diluted $ (0.22) $ (0.98) $ (0.67) $ (2.66)
Weighted average common shares outstanding, basic 8,817,316 2,274,113 7,640,192 1,667,527
Weighted average common shares outstanding, diluted 8,817,316 2,274,113 7,640,192 1,667,527
v3.24.2.u1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2022 $ 53 $ 107,216,566 $ (110,931,063) $ (315,208) $ (4,029,652)
Balance, shares at Dec. 31, 2022 534,490        
Settlement of restricted stock units
Settlement of restricted stock units, shares 624        
Public offerings, net $ 139 9,049,865 9,050,004
Public offerings, net, shares 1,381,619        
Transaction costs associated with public offerings (447,879) (447,879)
Issuance of common stock upon exercise of warrants $ 30 (30)
Issuance of common stock upon exercise of warrants, shares 300,897        
Stock-based compensation 194,550   194,550
Deemed dividend related to warrants down round provision 12,038 (12,038)
Net loss (4,420,107) (11,001) (4,431,108)
Settlement of commitment fee $ 4 399,996 400,000
Settlement of commitment fee, shares 44,444        
Conversion of convertible notes $ 41 3,056,851 3,056,892
Conversion of convertible notes, shares 408,580        
Reverse split fractional shares
Reverse split fractional shares, shares (862)        
Balance at Jun. 30, 2023 $ 267 119,481,957 (115,363,208) (326,209) 3,792,807
Balance, shares at Jun. 30, 2023 2,669,792        
Balance at Mar. 31, 2023 $ 128 113,293,834 (113,127,237) (319,149) (152,424)
Balance, shares at Mar. 31, 2023 1,284,583        
Settlement of restricted stock units
Settlement of restricted stock units, shares 312        
Public offerings, net $ 109 6,360,843 6,360,952
Public offerings, net, shares 1,084,000        
Transaction costs associated with public offerings (253,836) (253,836)
Issuance of common stock upon exercise of warrants $ 30 (30)
Issuance of common stock upon exercise of warrants, shares 300,897        
Stock-based compensation 77,417 77,417
Deemed dividend related to warrants down round provision 3,729 (3,729)
Net loss   (2,232,242) (7,060) (2,239,302)
Balance at Jun. 30, 2023 $ 267 119,481,957 (115,363,208) (326,209) 3,792,807
Balance, shares at Jun. 30, 2023 2,669,792        
Balance at Dec. 31, 2023 $ 315 121,233,901 (121,557,074) (328,409) (651,267)
Balance, shares at Dec. 31, 2023 3,146,076        
Settlement of restricted stock units
Settlement of restricted stock units, shares 63        
Issuance of common stock upon exercise of warrants $ 132 2,075,087 2,075,219
Issuance of common stock upon exercise of warrants, shares 1,323,904        
Stock-based compensation 59,756 59,756
Deemed dividend related to warrants down round provision 290 (290)
Net loss (5,084,282) (74) (5,084,356)
Issuance of common stock upon warrant inducement, net of issuance costs $ 293 4,718,002 4,718,295
Issuance of common stock upon warrant inducement, net of issuance costs, shares 2,935,608        
Conversion of convertible notes $ 75 1,168,525 $ 1,168,600
Conversion of convertible notes, shares 745,521       745,521
Transaction costs associated with warrant inducement (806,862) $ (806,862)
Balance at Jun. 30, 2024 $ 815 128,448,699 (126,641,646) (328,483) 1,479,385
Balance, shares at Jun. 30, 2024 8,151,172        
Balance at Mar. 31, 2024 $ 733 128,422,232 (124,673,853) (328,483) 3,420,629
Balance, shares at Mar. 31, 2024 7,329,172        
Stock-based compensation 26,549 26,549
Net loss (1,967,793) (1,967,793)
Issuance of common stock upon warrant inducement, net of issuance costs $ 82 (82)
Issuance of common stock upon warrant inducement, net of issuance costs, shares 822,000        
Balance at Jun. 30, 2024 $ 815 $ 128,448,699 $ (126,641,646) $ (328,483) $ 1,479,385
Balance, shares at Jun. 30, 2024 8,151,172        
v3.24.2.u1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities:    
Net loss $ (5,084,356) $ (4,431,108)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest and interest expense related to note conversions 29,113 1,497
Amortization of original issue discount and debt issuance costs 1,197,200
Change in fair value of convertible notes (146,479)
Change in fair value of liability classified warrants (16,773) (262,650)
Stock-based compensation 59,756 194,550
Lease cost (90)
Changes in operating assets and liabilities:    
Unbilled receivable (126,662) 169,243
Prepaid expenses and other assets 190,909 469,404
Accounts payable (1,795,404) (1,669,162)
Accrued expenses and other liabilities (172,077) (1,040,666)
Net cash used in operating activities (5,718,294) (6,715,461)
Cash flows from financing activities:    
Proceeds public offering, net 9,050,004
Proceeds from warrant exercises 2,075,219
Proceeds from warrant inducement, net of issuance costs 4,718,295
Transaction costs associated with public offering (447,879)
Transaction costs associated with warrant inducement (465,494)
Repayment of convertible notes (485,190) (1,000,208)
Repayment of financed insurance premiums (204,909) (204,676)
Net cash provided by financing activities 5,637,921 7,397,241
Increase (decrease) in cash and cash equivalents (80,373) 681,780
Cash and cash equivalents beginning of period 1,123,604 3,147,702
Cash and cash equivalents end of period 1,043,231 3,829,482
Supplemental disclosure of non-cash investing and financing activities:    
Incremental fair value of February 2024 warrant inducement 5,167,372
Conversions of convertible notes into common stock 1,168,600 3,056,892
Transaction costs from warrant inducement 341,368
Deemed dividend related to warrants down round provision 290 12,038
Financed insurance premiums 235,155 445,737
Settlement of commitment fee in shares $ 400,000
v3.24.2.u1
ORGANIZATION AND PRINCIPAL ACTIVITIES
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
ORGANIZATION AND PRINCIPAL ACTIVITIES

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Ensysce Biosciences, Inc. (“Ensysce”), along with its 79.2%-owned subsidiary, EBIR, Inc. (“EBIR”, formerly known as Covistat, Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is its program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR® (Multi-Pill Abuse Resistant) technology for overdose protection which will be applied to the PF614 program. The Company is also applying its TAAP and MPAR® technology to a methadone prodrug for use in the treatment of Opioid Use Disorder.

 

In 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the certificate of incorporation, EBIR was authorized to issue 1,000,000 shares of common stock, $0.001 par value per share, and 100,000 shares of preferred stock, $0.001 par value per share. Ensysce is a 79.2% stockholder in EBIR, with 9.9% and 10.9% of the shares held by a certain key person of the Company and two unrelated parties, respectively. The non-Ensysce owned shares and the activity are reflected on the financial statements as Noncontrolling interests.

 

The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

 
v3.24.2.u1
BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION

NOTE 2 - BASIS OF PRESENTATION

 

The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.

 

In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2023, which may be found in the Company’s Form 10-K filed with the SEC on March 15, 2024.

 

Going concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.

 

The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

 

While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.

 

The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of estimates and assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.

 

Cash and cash equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as two research and development vendors made up greater than 10% individually, and 31% and 38% in aggregate, of the outstanding accounts payable balance as of June 30, 2024 and December 31, 2023, respectively.

 

Property and equipment

 

Property and equipment are fully depreciated and as such there is no depreciation expense recognized in the periods presented.

 

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Pursuant to ASC 820, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of June 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

 

Warrants

 

The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants.

 

The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023.

 

   Total   Level 1   Level 2   Level 3 
   June 30, 2024 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants  $9,615   $      -   $       -   $9,615 
Total  $9,615   $-   $-   $9,615 

 

   Total   Level 1   Level 2   Level 3 
   December 31, 2023 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants   26,388          -           -    26,388 
Total  $26,388   $-   $-   $26,388 

 

The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024):

   Liability
classified
warrants		 
Fair value, December 31, 2023  $26,388 
Change in fair value   (16,773)
Fair value, June 30, 2024  $9,615 

 

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR® overdose prevention technology (the “MPAR Grant”). The initial grant was extended several times and cumulative funding under this grant of approximately $10.7 million was completed in December 2023.

 

 

In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $5.4 million and the current grant period ends August 31, 2024. As of June 30, 2024, the remaining cash funding under the grant is $1.9 million.

 

The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
MPAR  $-   $437,263   $-   $918,542 
TAAP/OUD   181,797    53,209    487,519    361,565 
Total  $181,797   $490,472   $487,519   $1,280,107 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded.

 

Research and development costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 

General and administrative expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 

Stock-based compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.

 

 

Income taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 

Net loss per share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period.

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below):

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Stock options   580,188    26,354    580,188    26,354 
RSUs   -    377    -    377 
Warrants   11,005,004    3,017,026    10,373,633    1,938,542 
Convertible notes   137,799    -    137,799    - 
Total   11,722,991    3,043,757    11,091,620    1,965,273 

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company.

 

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

 

 
v3.24.2.u1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 6 Months Ended
Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following:

   June 30,
2024		   December 31,
2023		 
Prepaid research and development  $539,208   $535,474 
Prepaid insurance   418,215    441,871 
Other prepaid expenses   170,439    72,358 
Other current assets   64,421    18,000 
Total prepaid expenses and other current assets  $1,192,283   $1,067,703 

 
v3.24.2.u1
ACCRUED EXPENSES AND OTHER LIABILITIES
 6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER LIABILITIES

NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consisted of the following:

   June 30,
2024		   December 31,
2023		 
Accrued research and development  $208,992   $329,228 
Professional fees   26,950    110,202 
Other accrued liabilities   134,244    102,830 
Total accrued expenses and other liabilities  $370,186   $542,260 

 
v3.24.2.u1
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

Purchase Commitments

 

As of June 30, 2024, the Company’s commitments included approximately $16 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services.

 

Litigation

 

As of June 30, 2024, and December 31, 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

 

 

Lease

 

The Company’s current lease agreement (as amended) has a term that extends through October 31, 2024, with no contracted option to renew. As of June 30, 2024, the future lease payments totaled $11,363. The Company recognized total rent expense of $8,747 and $17,495 in the three and six months ended June 30, 2024 and $8,375 and $16,749 in the three and six-months ended June 30, 2023.

 

Share Subscription Facility

 

In December 2020, the Company executed the GEM Agreement, under which an investor agreed to provide the Company with a share subscription facility of up to $60.0 million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. Concurrent with the public listing of the Company’s shares on July 2, 2021, the Company issued to the investor 4,608 warrants with a three-year term to purchase common stock of Ensysce at an exercise price of $2,402.40 per share, subsequently reduced to $1.06 at February 12, 2024 (Note 8). Usage of the GEM facility is limited by other agreements of the Company. The Company has not raised any capital to date pursuant to the GEM facility.

 
v3.24.2.u1
NOTES PAYABLE
 6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 7 – NOTES PAYABLE

 

The following table provides a summary of the Company’s outstanding debt as of June 30, 2024:

   Principal
balance		   Accrued
interest		   Net debt
balance		 
2023 Notes  $216,000    6,308 -  222,308 
Financed insurance   232,155    - -  232,155 
Total  $448,155   $6,308 - $454,463 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2023:

 

   December 31, 2023 
   Principal
balance		   Accrued
interest		   Unamortized Debt
Discount and
Issuance Costs		   Net debt
balance		 
2023 Notes  $1,836,000   $13,078   $(1,197,200)  $651,878 
Financed insurance   197,249    5,570    -    202,819 
Total  $2,033,249   $18,648   $(1,197,200)  $854,697 

 

 

Interest Expense

 

The interest expense recognized for financed insurance was $148 and $2,092 for the three and six months ended June 30, 2024 and $0 and $1,497 for the three and six months ended June 30, 2023. Interest expense recognized for the 2023 Notes was $27,563 and $1.3 million for the three and six months ended June 30, 2024, which consists of amortization of the debt discount and debt issuance costs and incurred and accrued interest.

 

2023 Notes

 

On October 23, 2023, the Company entered into a Securities Purchase Agreement (“SPA”) for an aggregate financing of $1.8 million with investors, including $0.2 million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $612,000 for an aggregate purchase price of $566,667 and (ii) warrants to purchase 1,255,697 shares of the Company’s common stock, par value $0.0001 per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors referenced above, (i) additional notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333 and (ii) additional warrants to purchase 2,511,394 shares of the common stock in the aggregate. The notes were scheduled to mature on April 25, 2024 and May 28, 2024, respectively.

 

The combined notes are subject to an original issue discount of 8%, have an original term of six months from their respective date of issuance and accrue interest at the rate of 6.0% per annum. The notes are convertible into common stock, at a per share conversion price equal to $1.5675. Beginning ninety days following issuance of the respective notes, the Company was obligated to redeem monthly one third of the original principal amount under the applicable note, plus accrued but unpaid interest, liquidated damages and any other amounts then owing to the holder of such note. The Company is required to pay the redemption amount in cash with a premium of 10% or, at the election of the purchaser at any time, some or all of the principal amount and interest may be paid by conversion of shares under the note into common stock based on a conversion price equal to $1.5675. The Company determined the 2023 Notes are to be accounted for as conventional convertible debt as they provide for the holder an option to convert the outstanding balances into a fixed number of shares (or an equivalent amount of cash at the discretion of the Company) and the option to convert meets the definition of an exception from derivative accounting. As a result, the Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of the balance sheet. The amortization of the original debt discount (approximately $0.1 million) and issuance costs (approximately $0.3 million) was recorded as interest expense within the consolidated statements of operations. As of June 30, 2024, the original debt discount and issuance costs were fully amortized to interest expense.

 

The warrants have an exercise price of $1.5675, the same as the conversion price, and are exercisable for five years following the issuance date. The warrants were equity classified as they are indexed to the Company’s stock and only settleable in shares. The warrants were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative fair value method. The initial fair value of $1.1 million allocated to the warrants was considered a debt discount and will be amortized to interest expense over the remaining term of the notes. As of June 30, 2024, the discount associated with the warrants was fully amortized to interest expense.

 

 

During 2024, the Company converted 745,521 shares of common stock with a conversion value of $1.2 million related to the 2023 Notes. In addition, in connection with the SPA, the Company incurred a $1.0 million waiver fee in connection to the 2024 Warrant Inducement (see Note 8) to pay down $0.5 million of 2023 Notes and $0.5 million in transaction costs recorded as such in the consolidated statement of stockholders’ equity. As of June 30, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible promissory notes held with a Company board member (see Note 10).

 

Financed insurance premiums

 

In June 2024, the Company renewed and financed its directors’ and officers’ liability insurance in the amount of $0.2 million. Monthly payments are scheduled from July 2024 through March 2025.

 
v3.24.2.u1
STOCKHOLDERS’ EQUITY
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 8 - STOCKHOLDERS’ EQUITY

 

The Company’s current Certificate of Incorporation authorizes 250,000,000 shares of common stock and 1,500,000 shares of preferred stock, both with par value equal to $0.0001. As of June 30, 2024, and December 31, 2023, there were no shares of preferred stock issued and outstanding.

 

2024 Warrant Inducement

 

On February 12, 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of 3,601,752 shares of Common Stock at a reduced exercise price of $1.31 per share in consideration of the Company’s agreement to issue new unregistered Series A Warrants (the “Series A Warrants”) to purchase up to 3,601,752 shares of Common Stock and new unregistered Series B Warrants (the “Series B Warrants”) to purchase up to 3,601,752 shares of Common Stock (collectively, the “New Warrant Shares”). The Series A Warrants have an exercise price of $1.06 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an exercise price of $1.06 per share and will expire on May 12, 2028. The gross proceeds to the Company from the exercise of the warrants were approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses. As the existing warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $5.2 million as an equity issuance cost.

 

In connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes’ SPA it had entered as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note 7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant inducement.

 

The Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $0.3 million in legal fees and other closing costs. Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement agent warrants expire on May 12, 2028, and have an exercise price of $1.6375 per share of Common Stock (equal to 125% of the reduced exercise price per Existing Warrant).

 

The closing of the offering occurred on February 14, 2024.

 

 

Abeyance Shares

 

Related to the 2024 Warrant Inducement, a holder left 1,488,144 shares in abeyance at the Company’s transfer agent to be delivered to the holder at their request. During the quarter ended June 30, 2024, 822,000 shares held in abeyance were delivered to the holder and the remaining shares are held in abeyance. Accordingly, as of June 30, 2024, 666,144 shares were held in abeyance, have not been issued and are not outstanding.

 

Warrants

 

The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2024:

Reference  Shares
Underlying
Outstanding
Warrants		   Exercise
Price		   Description  Classification
(a)   63,659   $2,400.00 - 2,760.00   LACQ warrants  Equity
(b)   4,608   $1.31   Share subscription facility  Equity
(c)   4,518   $3.64   2021 Notes  Liability
(d)   38,900   $3.64   2022 Notes  Liability
(e)   549,993   $3.64 - 16.80   Public offering  Equity
(f)   318,451   $8.58 - 12.60   Public offering  Equity
(g)   126,061   $4.86   Public offering  Equity
(h)   2,443,187   $1.57   2023 Notes  Equity
(i)   7,455,627   $1.06 - 1.64   2024 Warrants  Equity
    11,005,004            

 

(a) On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 warrants previously issued by LACQ (subsequently in December 2022 and August 2023, 7,782 and 7,310 warrants, respectively, were cancelled). The warrants provide holders the right to purchase common stock at a strike price of between $2,400.00 and $2,760.00 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 41,666 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 21,993 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 warrants issued on June 30, 2021 from $2,760.00 to $2,400.00 per share.
   
(b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an initial exercise price of $2,402.40 per share. The warrants have been subject to multiple exercise price reductions as required by a down-round adjustment feature of the warrant, due to common stock issued at prices below the then current exercise price. The adjustments have progressed from the original exercise price of $2,402.40 per share to the current exercise price at June 30, 2024 of $1.06 per share. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a Black-Scholes model) is reflected on the consolidated statement of operations as a deemed dividend.

 

 

(c) On September 24, 2021 and November 5, 2021, the Company issued 1,507 and 3,011 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $1,831.20 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026 and November 4, 2026, respectively. As a result of the issuance of the 2022 Notes in July 2022, the exercise price of these warrants was adjusted down to $187.20. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(d) On July 1, 2022 and August 9, 2022, the Company issued 19,450 warrants each in connection with the issuance of the 2022 Notes. The warrants were immediately exercisable with an exercise price of $170.04 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on June 29, 2027 and August 8, 2027, respectively. As a result of the issuance of shares and warrants in connection with the December 2022 public offering, the exercise price of these warrants was adjusted down to $24.07. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(e) On December 9, 2022, the Company issued 549,993 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $16.80 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on December 9, 2027. On May 12, 2023, in exchange for $0.125 per applicable warrant, the Company amended 166,667 of these warrants to reduce their exercise price to $3.64.
   
(f) On February 6, 2023, the Company issued 318,451 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $8.58 - $12.60 and expire on February 2, 2028, and August 7, 2028.
   
(g) On May 12, 2023, the Company issued 3,727,813 equity classified warrants (Series A-1, A-2, and placement agent warrants) in connection with a public offering. The warrants were immediately exercisable with an exercise price of $3.64 - $4.86 and expire on November 12, 2024, May 10, 2028, and May 12, 2028. In connection to the Inducement Letter entered into February 12, 2024, certain existing warrant holders agreed to exercise 3,601,752 Series A-1 and A-2 warrants at a reduced exercise price of $1.31. The placement agent warrants remain outstanding as of June 30, 2024.
   
(h)

On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 shares and 2,511,394 shares, respectively. The warrants were immediately exercisable with an exercise price of $1.5675 and expire on October 25, 2028 and November 28, 2028, respectively. In January 2024, a holder of the warrants exercised 1,323,904 warrants at an exercise price of $1.5675.

 

(i) On February 12, 2024, the Company issued 7,455,627 equity classified warrants (Series A Warrants, Series B Warrants and placement agent warrants) in connection with the Inducement Letter for the 2024 warrant inducement and related warrant restructuring. The Series A and Series B Warrants were immediately exercisable with an exercise price of $1.06 and expire on August 14, 2025 and May 12, 2028, respectively. The placement agent warrants were immediately exercisable with an exercise price of $1.6375 and expire on May 12, 2028.

 

 

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

   Stock price   Exercise price   Expected term (years)   Volatility   Risk free rate 
(a) LACQ warrants (grant date varies)  $3,477.60   $2,400.00 - $2,760.00     3.00    110.0%   0.5%
(b) Share subscription facility (grant date 7/2/21)  $3,477.60   $2,402.40    3.00    110.0%   0.5%
(b) Share subscription facility (remeasurement date varies)  $1.13 - $1,029.60    $1.06- $680.23     0.38 - 2.58    91.3% - 140.5%    1.04% - 5.43% 
(c) Liability classified warrants (grant date 9/24/21)  $1,077.60   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (grant date 11/5/21)  $540   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    2.25 - 2.35    133.7% - 135.4%    4.6%
(d) Liability classified warrants (grant date 7/1/22)  $136.80   $170.04    5.00    98.9%   2.9%
(d) Liability classified warrants (grant date 8/9/22)  $127.20   $170.04    5.00    102.8%   3.0%
(d) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    3.00 - 3.11    126.7% - 128.6%    4.4%

 
v3.24.2.u1
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 9 - STOCK-BASED COMPENSATION

 

In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2023, the Company’s Board approved an annual increase of 26,725 shares and in August 2023, the Company’s stockholders approved a proposal for an increase of 585,796 shares available for future grant under the 2021 Omnibus Plan.

 

The Company recognized stock-based compensation expense within general and administrative expense of $18,658 and $42,146 for the three and six months ended June 30, 2024 and $60,394 and $156,663 for the three and six months ended June 30, 2023. The Company recognized stock-based compensation expense within research and development expense of $7,891 and $17,610 for the three and six months ended June 30, 2024 and $17,023 and $37,887 for the three and six months ended June 30, 2023.

 

Option Activity

 

There were no stock options granted during the six months ended June 30, 2024 and June 30, 2023.

 

The following table summarizes the Company’s stock option activity during the six months ended June 30, 2024:

       Weighted average     
   Options   Exercise price   Remaining contractual life   Intrinsic value 
Outstanding at December 31, 2023   581,314   $33.15    9.57   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired / Forfeited   -    -    -    - 
Outstanding at June 30, 2024   581,314    33.15    9.08    - 
Exercisable at June 30, 2024   580,188    32.28    -    - 
Vested and expected to vest   581,314    33.15    9.08    - 

 

 

Option Valuation

 

The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in during the six months ended June 30, 2024 and 2023):

 

  ● Expected stock-price volatility. The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
  ● Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
  ● Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
  ● Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.

 

As of June 30, 2024, the Company had an aggregate of $60,092 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 0.95 years.

 

Shares Reserved for Future Issuance

 

The following shares of common stock are reserved for future issuance:

   June 30, 2024 
Awards outstanding under the 2021 Omnibus Incentive Plan   581,314 
Awards available for future grant under 2021 Omnibus Incentive Plan   2,112 
Warrants outstanding   11,005,004 
Total shares of common stock reserved for future issuance   11,588,430 

 
v3.24.2.u1
RELATED PARTIES
 6 Months Ended
Jun. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTIES

NOTE 10 - RELATED PARTIES

 

As of June 30, 2024, the Company held a $0.2 million senior secured convertible promissory note plus accrued interest and 0.4 million warrants exercisable for common stock at $1.5675 per share issued from a board member in connection to the issuance of the 2023 Notes. On April 25, 2024, the Company and the board member entered into a forbearance agreement that will expire on April 25, 2025. Upon termination of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company may pay the notes in full at any time prior to the conclusion of the forbearance period.
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Use of estimates and assumptions

Use of estimates and assumptions

 

Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.

 
Cash and cash equivalents

Cash and cash equivalents

 

For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

 
Concentrations of credit risk and off-balance sheet risk

Concentrations of credit risk and off-balance sheet risk

 

Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as two research and development vendors made up greater than 10% individually, and 31% and 38% in aggregate, of the outstanding accounts payable balance as of June 30, 2024 and December 31, 2023, respectively.

 
Property and equipment

Property and equipment

 

Property and equipment are fully depreciated and as such there is no depreciation expense recognized in the periods presented.

 
Fair Value Measurement

Fair Value Measurement

 

ASC 820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Pursuant to ASC 820, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
  Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.

 

As of June 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items.

 

 

Warrants

 

The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants.

 

The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023.

 

   Total   Level 1   Level 2   Level 3 
   June 30, 2024 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants  $9,615   $      -   $       -   $9,615 
Total  $9,615   $-   $-   $9,615 

 

   Total   Level 1   Level 2   Level 3 
   December 31, 2023 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants   26,388          -           -    26,388 
Total  $26,388   $-   $-   $26,388 

 

The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024):

   Liability
classified
warrants		 
Fair value, December 31, 2023  $26,388 
Change in fair value   (16,773)
Fair value, June 30, 2024  $9,615 

 

Federal Grants

 

In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR® overdose prevention technology (the “MPAR Grant”). The initial grant was extended several times and cumulative funding under this grant of approximately $10.7 million was completed in December 2023.

 

 

In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $5.4 million and the current grant period ends August 31, 2024. As of June 30, 2024, the remaining cash funding under the grant is $1.9 million.

 

The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.

 

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
MPAR  $-   $437,263   $-   $918,542 
TAAP/OUD   181,797    53,209    487,519    361,565 
Total  $181,797   $490,472   $487,519   $1,280,107 

 

Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded.

 
Research and development costs

Research and development costs

 

The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

 
General and administrative expenses

General and administrative expenses

 

General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.

 
Stock-based compensation

Stock-based compensation

 

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations.

 

From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.

 

 
Income taxes

Income taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

 
Net loss per share

Net loss per share

 

The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period.

 

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below):

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Stock options   580,188    26,354    580,188    26,354 
RSUs   -    377    -    377 
Warrants   11,005,004    3,017,026    10,373,633    1,938,542 
Convertible notes   137,799    -    137,799    - 
Total   11,722,991    3,043,757    11,091,620    1,965,273 

 
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company.

 

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023.

 

   Total   Level 1   Level 2   Level 3 
   June 30, 2024 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants  $9,615   $      -   $       -   $9,615 
Total  $9,615   $-   $-   $9,615 

 

   Total   Level 1   Level 2   Level 3 
   December 31, 2023 
   Total   Level 1   Level 2   Level 3 
Liability classified warrants   26,388          -           -    26,388 
Total  $26,388   $-   $-   $26,388 
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3

The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024):

   Liability
classified
warrants		 
Fair value, December 31, 2023  $26,388 
Change in fair value   (16,773)
Fair value, June 30, 2024  $9,615 
SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS

The revenue recognized under the MPAR Grant and OUD Grant was as follows:

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
MPAR  $-   $437,263   $-   $918,542 
TAAP/OUD   181,797    53,209    487,519    361,565 
Total  $181,797   $490,472   $487,519   $1,280,107 
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES

The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below):

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Stock options   580,188    26,354    580,188    26,354 
RSUs   -    377    -    377 
Warrants   11,005,004    3,017,026    10,373,633    1,938,542 
Convertible notes   137,799    -    137,799    - 
Total   11,722,991    3,043,757    11,091,620    1,965,273 
v3.24.2.u1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
 6 Months Ended
Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

   June 30,
2024		   December 31,
2023		 
Prepaid research and development  $539,208   $535,474 
Prepaid insurance   418,215    441,871 
Other prepaid expenses   170,439    72,358 
Other current assets   64,421    18,000 
Total prepaid expenses and other current assets  $1,192,283   $1,067,703 
v3.24.2.u1
ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)
 6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consisted of the following:

   June 30,
2024		   December 31,
2023		 
Accrued research and development  $208,992   $329,228 
Professional fees   26,950    110,202 
Other accrued liabilities   134,244    102,830 
Total accrued expenses and other liabilities  $370,186   $542,260 
v3.24.2.u1
NOTES PAYABLE (Tables)
 6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
SCHEDULE OF DEBT

The following table provides a summary of the Company’s outstanding debt as of June 30, 2024:

   Principal
balance		   Accrued
interest		   Net debt
balance		 
2023 Notes  $216,000    6,308 -  222,308 
Financed insurance   232,155    - -  232,155 
Total  $448,155   $6,308 - $454,463 

 

The following table provides a summary of the Company’s outstanding debt as of December 31, 2023:

 

   December 31, 2023 
   Principal
balance		   Accrued
interest		   Unamortized Debt
Discount and
Issuance Costs		   Net debt
balance		 
2023 Notes  $1,836,000   $13,078   $(1,197,200)  $651,878 
Financed insurance   197,249    5,570    -    202,819 
Total  $2,033,249   $18,648   $(1,197,200)  $854,697 
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Tables)
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
SCHEDULE OF OUTSTANDING WARRANT

The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2024:

Reference  Shares
Underlying
Outstanding
Warrants		   Exercise
Price		   Description  Classification
(a)   63,659   $2,400.00 - 2,760.00   LACQ warrants  Equity
(b)   4,608   $1.31   Share subscription facility  Equity
(c)   4,518   $3.64   2021 Notes  Liability
(d)   38,900   $3.64   2022 Notes  Liability
(e)   549,993   $3.64 - 16.80   Public offering  Equity
(f)   318,451   $8.58 - 12.60   Public offering  Equity
(g)   126,061   $4.86   Public offering  Equity
(h)   2,443,187   $1.57   2023 Notes  Equity
(i)   7,455,627   $1.06 - 1.64   2024 Warrants  Equity
    11,005,004            

 

(a) On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 warrants previously issued by LACQ (subsequently in December 2022 and August 2023, 7,782 and 7,310 warrants, respectively, were cancelled). The warrants provide holders the right to purchase common stock at a strike price of between $2,400.00 and $2,760.00 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 41,666 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 21,993 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
   
  On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 warrants issued on June 30, 2021 from $2,760.00 to $2,400.00 per share.
   
(b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an initial exercise price of $2,402.40 per share. The warrants have been subject to multiple exercise price reductions as required by a down-round adjustment feature of the warrant, due to common stock issued at prices below the then current exercise price. The adjustments have progressed from the original exercise price of $2,402.40 per share to the current exercise price at June 30, 2024 of $1.06 per share. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a Black-Scholes model) is reflected on the consolidated statement of operations as a deemed dividend.

 

 

(c) On September 24, 2021 and November 5, 2021, the Company issued 1,507 and 3,011 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $1,831.20 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026 and November 4, 2026, respectively. As a result of the issuance of the 2022 Notes in July 2022, the exercise price of these warrants was adjusted down to $187.20. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(d) On July 1, 2022 and August 9, 2022, the Company issued 19,450 warrants each in connection with the issuance of the 2022 Notes. The warrants were immediately exercisable with an exercise price of $170.04 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on June 29, 2027 and August 8, 2027, respectively. As a result of the issuance of shares and warrants in connection with the December 2022 public offering, the exercise price of these warrants was adjusted down to $24.07. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
   
(e) On December 9, 2022, the Company issued 549,993 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $16.80 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on December 9, 2027. On May 12, 2023, in exchange for $0.125 per applicable warrant, the Company amended 166,667 of these warrants to reduce their exercise price to $3.64.
   
(f) On February 6, 2023, the Company issued 318,451 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $8.58 - $12.60 and expire on February 2, 2028, and August 7, 2028.
   
(g) On May 12, 2023, the Company issued 3,727,813 equity classified warrants (Series A-1, A-2, and placement agent warrants) in connection with a public offering. The warrants were immediately exercisable with an exercise price of $3.64 - $4.86 and expire on November 12, 2024, May 10, 2028, and May 12, 2028. In connection to the Inducement Letter entered into February 12, 2024, certain existing warrant holders agreed to exercise 3,601,752 Series A-1 and A-2 warrants at a reduced exercise price of $1.31. The placement agent warrants remain outstanding as of June 30, 2024.
   
(h)

On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 shares and 2,511,394 shares, respectively. The warrants were immediately exercisable with an exercise price of $1.5675 and expire on October 25, 2028 and November 28, 2028, respectively. In January 2024, a holder of the warrants exercised 1,323,904 warrants at an exercise price of $1.5675.

 

(i) On February 12, 2024, the Company issued 7,455,627 equity classified warrants (Series A Warrants, Series B Warrants and placement agent warrants) in connection with the Inducement Letter for the 2024 warrant inducement and related warrant restructuring. The Series A and Series B Warrants were immediately exercisable with an exercise price of $1.06 and expire on August 14, 2025 and May 12, 2028, respectively. The placement agent warrants were immediately exercisable with an exercise price of $1.6375 and expire on May 12, 2028.
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS

The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows:

   Stock price   Exercise price   Expected term (years)   Volatility   Risk free rate 
(a) LACQ warrants (grant date varies)  $3,477.60   $2,400.00 - $2,760.00     3.00    110.0%   0.5%
(b) Share subscription facility (grant date 7/2/21)  $3,477.60   $2,402.40    3.00    110.0%   0.5%
(b) Share subscription facility (remeasurement date varies)  $1.13 - $1,029.60    $1.06- $680.23     0.38 - 2.58    91.3% - 140.5%    1.04% - 5.43% 
(c) Liability classified warrants (grant date 9/24/21)  $1,077.60   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (grant date 11/5/21)  $540   $1,831.20    5.00    94.1%   1.0%
(c) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    2.25 - 2.35    133.7% - 135.4%    4.6%
(d) Liability classified warrants (grant date 7/1/22)  $136.80   $170.04    5.00    98.9%   2.9%
(d) Liability classified warrants (grant date 8/9/22)  $127.20   $170.04    5.00    102.8%   3.0%
(d) Liability classified warrants (remeasured at 6/30/24)  $0.50   $3.64    3.00 - 3.11    126.7% - 128.6%    4.4%
v3.24.2.u1
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
SCHEDULE OF STOCK OPTION ACTIVITY

The following table summarizes the Company’s stock option activity during the six months ended June 30, 2024:

       Weighted average     
   Options   Exercise price   Remaining contractual life   Intrinsic value 
Outstanding at December 31, 2023   581,314   $33.15    9.57   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Expired / Forfeited   -    -    -    - 
Outstanding at June 30, 2024   581,314    33.15    9.08    - 
Exercisable at June 30, 2024   580,188    32.28    -    - 
Vested and expected to vest   581,314    33.15    9.08    - 
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE

The following shares of common stock are reserved for future issuance:

   June 30, 2024 
Awards outstanding under the 2021 Omnibus Incentive Plan   581,314 
Awards available for future grant under 2021 Omnibus Incentive Plan   2,112 
Warrants outstanding   11,005,004 
Total shares of common stock reserved for future issuance   11,588,430 
v3.24.2.u1
ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2020
Common stock, shares authorized 250,000,000 250,000,000  
Common stock, par value $ 0.0001 $ 0.0001  
Preferred stock, shares authorized 1,500,000 1,500,000  
Preferred stock, par value $ 0.0001 $ 0.0001  
EBIR, Inc [Member]      
Ownership percentage 79.20%    
Common stock, shares authorized     1,000,000
Common stock, par value     $ 0.001
Preferred stock, shares authorized     100,000
Preferred stock, par value     $ 0.001
EBIR, Inc [Member] | Key Personnel [Member]      
Ownership percentage 9.90%    
EBIR, Inc [Member] | Unrelated Party [Member]      
Ownership percentage 10.90%    
v3.24.2.u1
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]    
Liability classified warrants $ 9,615 $ 26,388
Total 9,615 26,388
Fair Value, Inputs, Level 1 [Member]    
Platform Operator, Crypto Asset [Line Items]    
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]    
Platform Operator, Crypto Asset [Line Items]    
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]    
Platform Operator, Crypto Asset [Line Items]    
Liability classified warrants 9,615 26,388
Total $ 9,615 $ 26,388
v3.24.2.u1
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details) - Liability Classified Warrants [Member]
 6 Months Ended
Jun. 30, 2024
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance $ 26,388
Change in fair value (16,773)
Ending balance $ 9,615
v3.24.2.u1
SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Product Information [Line Items]        
Total $ 181,797 $ 490,472 $ 487,519 $ 1,280,107
MPAR [Member]        
Product Information [Line Items]        
Total 437,263 918,542
TAAP/OUD [Member]        
Product Information [Line Items]        
Total $ 181,797 $ 53,209 $ 487,519 $ 361,565
v3.24.2.u1
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 11,722,991 3,043,757 11,091,620 1,965,273
Share-Based Payment Arrangement, Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 580,188 26,354 580,188 26,354
Restricted Stock Units (RSUs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 377 377
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 11,005,004 3,017,026 10,373,633 1,938,542
Convertible Debt Securities [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 137,799 137,799
v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Sep. 30, 2019
Product Information [Line Items]      
Concentration of risk two research and development vendors made up greater than 10% individually, and 31% and 38% in aggregate    
Depreciation $ 0 $ 0  
Grants receivable $ 1,900,000 $ 10,700,000 $ 5,400,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer [Member]      
Product Information [Line Items]      
Concentration of risk 31.00% 38.00%  
v3.24.2.u1
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid research and development $ 539,208 $ 535,474
Prepaid insurance 418,215 441,871
Other prepaid expenses 170,439 72,358
Other current assets 64,421 18,000
Total prepaid expenses and other current assets $ 1,192,283 $ 1,067,703
v3.24.2.u1
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued research and development $ 208,992 $ 329,228
Professional fees 26,950 110,202
Other accrued liabilities 134,244 102,830
Total accrued expenses and other liabilities $ 370,186 $ 542,260
v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Feb. 12, 2024
Jan. 31, 2024
May 12, 2023
Aug. 09, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jul. 02, 2021
Jun. 30, 2021
Dec. 31, 2020
Contractual obligation $ 16,000,000   $ 16,000,000                        
Future lease payments     11,363                        
Rent expense $ 8,747 $ 8,375 $ 17,495 $ 16,749                      
Common stock, subscriptions value                             $ 60,000,000.0
Warrants issued shares               19,450 19,450 3,011 1,507   4,608 78,751  
Warrant term                         3 years 5 years  
Warrant, exercise price $ 1.06   $ 1.06   $ 1.31 $ 1.5675 $ 3.64 $ 170.04 $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00   $ 2,760.00  
Investor [Member]                              
Warrants issued shares                         4,608    
Warrant term                         3 years    
Warrant, exercise price         $ 1.06               $ 2,402.40    
v3.24.2.u1
SCHEDULE OF DEBT (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Short-Term Debt [Line Items]    
Principal balance $ 448,155 $ 2,033,249
Accrued interest 6,308 18,648
Unamortized Debt Discount & Issuance Costs (1,197,200)
Net debt balance 454,463 854,697
2023 Notes [Member]    
Short-Term Debt [Line Items]    
Principal balance 216,000 1,836,000
Accrued interest 6,308 13,078
Unamortized Debt Discount & Issuance Costs (1,197,200)
Net debt balance 222,308 651,878
Financed Insurance [Member]    
Short-Term Debt [Line Items]    
Principal balance 232,155 197,249
Accrued interest 5,570
Unamortized Debt Discount & Issuance Costs  
Net debt balance $ 232,155 $ 202,819
v3.24.2.u1
SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - $ / shares
Nov. 29, 2023
Jun. 30, 2021
Jun. 30, 2024
Feb. 12, 2024
Jan. 31, 2024
Dec. 31, 2023
Nov. 28, 2023
Oct. 25, 2023
Aug. 31, 2023
May 12, 2023
Feb. 06, 2023
Dec. 31, 2022
Dec. 09, 2022
Aug. 09, 2022
Jul. 31, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jul. 02, 2021
Short-Term Debt [Line Items]                                        
Warrants issued   78,751                       19,450   19,450 3,011 1,507   4,608
Warrants cancelled                 7,310     7,782                
Warrant exercise price   $ 2,760.00 $ 1.06 $ 1.31 $ 1.5675         $ 3.64       $ 170.04   $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00  
Warrant expiration date   Jun. 30, 2026                       Aug. 08, 2027   Jun. 29, 2027 Nov. 04, 2026 Sep. 23, 2026    
Warrant term   5 years                                   3 years
Shares amended     250,000,000     250,000,000                            
Series B Warrants [Member]                                        
Short-Term Debt [Line Items]                                        
Warrants issued       3,601,752                                
Warrant exercise price       $ 1.06                                
Warrant expiration date       May 12, 2028                                
Series A Warrants [Member]                                        
Short-Term Debt [Line Items]                                        
Warrants issued       3,601,752                                
Warrant exercise price       $ 1.06                                
Warrant expiration date       Aug. 14, 2025                                
General and Administrative Expense [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price                                       $ 2,402.40
Public Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Class of warrant or right, outstanding   41,666                                    
Private Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Remaining of cashless warrant shares   21,993                                    
Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Warrants issued       3,601,752 1,323,904   2,511,394 1,255,697   3,727,813 318,451   549,993              
Warrant exercise price     $ 1.5675 $ 1.6375     $ 1.5675 $ 1.5675   $ 0.125     $ 16.80              
Warrant expiration date       May 12, 2028     Nov. 28, 2028 Oct. 25, 2028         Dec. 09, 2027              
Shares amended                   166,667                    
Warrant [Member] | Placement Agent Warrants [Member]                                        
Short-Term Debt [Line Items]                                        
Warrants issued       7,455,627                                
Warrant One [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant expiration date                     Feb. 02, 2028                  
Warrant Two [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant expiration date                     Aug. 07, 2028                  
Series A-1 Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant expiration date                   Nov. 12, 2024                    
Series A-2 Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant expiration date                   May 10, 2028                    
Placement Agent Warrants [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant expiration date                   May 12, 2028                    
Minimum [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price   $ 2,400.00 $ 2,402.40                                  
Minimum [Member] | Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price                   $ 3.64 $ 8.58                  
Maximum [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price   $ 2,760.00                                    
Maximum [Member] | Warrant [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price                   4.86 $ 12.60                  
Subscription Arrangement [Member]                                        
Short-Term Debt [Line Items]                                        
Warrants issued   2,083                                    
2023 Notes [Member] | First Securities Purchase Agreement [Member]                                        
Short-Term Debt [Line Items]                                        
Debt instrument maturity date Apr. 25, 2024                                      
2023 Notes [Member] | Second Securities Purchase Agreement [Member]                                        
Short-Term Debt [Line Items]                                        
Debt instrument maturity date May 28, 2024                                      
2022 Notes [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price                             $ 187.20          
2022 Notes and 2021 [Member]                                        
Short-Term Debt [Line Items]                                        
Warrant exercise price                   $ 0.125                    
v3.24.2.u1
NOTES PAYABLE (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 29, 2023
Oct. 25, 2023
Oct. 23, 2023
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Feb. 12, 2024
Jan. 31, 2024
Dec. 31, 2023
Nov. 28, 2023
May 12, 2023
Feb. 06, 2023
Dec. 09, 2022
Aug. 09, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jul. 02, 2021
Jun. 30, 2021
Short-Term Debt [Line Items]                                            
Interest expense         $ 148 $ 0 $ 2,092 $ 1,497                            
Aggregate principal amount       $ 448,155 $ 448,155   $ 448,155       $ 2,033,249                      
Warrants to purchase common shares                               19,450 19,450 3,011 1,507   4,608 78,751
Common stock, par value       $ 0.0001 $ 0.0001   $ 0.0001       $ 0.0001                      
Warrant, exercise price       $ 1.06 $ 1.06   $ 1.06   $ 1.31 $ 1.5675     $ 3.64     $ 170.04 $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00   $ 2,760.00
Conversion of shares             745,521                              
Conversion of shares value             $ 1,168,600 3,056,892                            
Transaction cost             4,718,295                            
Warrant inducement cost           4,718,295                              
Transaction cost             (806,862)                              
Financed insurance premiums       $ 200,000     $ 235,155 $ 445,737                            
Warrant [Member]                                            
Short-Term Debt [Line Items]                                            
Warrants to purchase common shares   1,255,697             3,601,752 1,323,904   2,511,394 3,727,813 318,451 549,993              
Warrant, exercise price   $ 1.5675   $ 1.5675 $ 1.5675   $ 1.5675   $ 1.6375     $ 1.5675 $ 0.125   $ 16.80              
Securities Purchase Agreement [Member]                                            
Short-Term Debt [Line Items]                                            
Aggregate purchase price     $ 1,800,000                                      
Warrant, exercise price     $ 1.5675                                      
Transaction cost             $ 1,000,000.0                              
Warrant inducement cost             500,000                              
Transaction cost             500,000                              
2023 Notes [Member]                                            
Short-Term Debt [Line Items]                                            
Interest expense         $ 27,563   1,300,000                              
Aggregate principal amount       $ 216,000 $ 216,000   216,000       $ 1,836,000                      
Amortization of debt discount premium             100,000                              
Amortization of financing costs             300,000                              
2023 Notes [Member] | Warrant [Member]                                            
Short-Term Debt [Line Items]                                            
Payments of debt issuance costs             $ 1,100,000                              
2023 Notes [Member] | Securities Purchase Agreement [Member]                                            
Short-Term Debt [Line Items]                                            
Aggregate purchase price     $ 200,000                                      
Original issue discount rate     8.00%                                      
Debt instrument accrue interest rate     6.00%                                      
Debt instrument conversion price     $ 1.5675                                      
Debt instrument redemption premium percentage     10.00%                                      
2023 Notes [Member] | First Closing Securities Purchase Agreement [Member]                                            
Short-Term Debt [Line Items]                                            
Aggregate purchase price   $ 566,667                                        
Aggregate principal amount   $ 612,000                                        
Warrants to purchase common shares   1,255,697                                        
Common stock, par value   $ 0.0001                                        
2023 Notes [Member] | Second Closing Securities Purchase Agreement [Member]                                            
Short-Term Debt [Line Items]                                            
Aggregate purchase price $ 1,133,333                                          
Aggregate principal amount $ 1,224,000                                          
Warrants to purchase common shares 2,511,394                                          
v3.24.2.u1
SCHEDULE OF OUTSTANDING WARRANT (Details) - $ / shares
 6 Months Ended
Jun. 30, 2024
Feb. 12, 2024
Jan. 31, 2024
Nov. 28, 2023
Oct. 25, 2023
May 12, 2023
Feb. 06, 2023
Dec. 09, 2022
Aug. 09, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jul. 02, 2021
Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants issued                 19,450 19,450 3,011 1,507   4,608 78,751
Warrants, exercise price $ 1.06 $ 1.31 $ 1.5675     $ 3.64     $ 170.04 $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00   $ 2,760.00
Warrant expiration date                 Aug. 08, 2027 Jun. 29, 2027 Nov. 04, 2026 Sep. 23, 2026     Jun. 30, 2026
December Public Offering [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants, exercise price                 $ 24.07 $ 24.07          
Warrant [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant 11,005,004                            
Warrants issued   3,601,752 1,323,904 2,511,394 1,255,697 3,727,813 318,451 549,993              
Warrants, exercise price $ 1.5675 $ 1.6375   $ 1.5675 $ 1.5675 $ 0.125   $ 16.80              
Warrant expiration date   May 12, 2028   Nov. 28, 2028 Oct. 25, 2028     Dec. 09, 2027              
Minimum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants, exercise price $ 2,402.40                           $ 2,400.00
Minimum [Member] | Warrant [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants, exercise price           3.64 $ 8.58                
Maximum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants, exercise price                             $ 2,760.00
Maximum [Member] | Warrant [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Warrants, exercise price           $ 4.86 $ 12.60                
Warrant One [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [1] 63,659                            
Warrant description [1] LACQ warrants                            
Warrant One [Member] | Minimum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [1] $ 2,400.00                            
Warrant One [Member] | Maximum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [1] $ 2,760.00                            
Warrant Two [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [2] 4,608                            
Exercise price [2] $ 1.31                            
Warrant description [2] Share subscription facility                            
Warrant Three [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [3] 4,518                            
Exercise price [3] $ 3.64                            
Warrant description [3] 2021 Notes                            
Warrant Four [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [4] 38,900                            
Exercise price [4] $ 3.64                            
Warrant description [4] 2022 Notes                            
Warrant Five [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [5] 549,993                            
Warrant description [5] Public offering                            
Warrant Five [Member] | Minimum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [5] $ 3.64                            
Warrant Five [Member] | Maximum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [5] $ 16.80                            
Warrant Six [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [6] 318,451                            
Warrant description [6] Public offering                            
Warrant Six [Member] | Minimum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [6] $ 8.58                            
Warrant Six [Member] | Maximum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [6] $ 12.60                            
Warrant Seven [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [7] 126,061                            
Exercise price [7] $ 4.86                            
Warrant description [7] Public offering                            
Warrant Eight [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [8] 2,443,187                            
Exercise price [8] $ 1.57                            
Warrant description [8] 2023 Notes                            
Warrant Nine [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Outstanding warrant [9] 7,455,627                            
Warrant description [9] 2024 Warrants                            
Warrant Nine [Member] | Minimum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [9] $ 1.06                            
Warrant Nine [Member] | Maximum [Member]                              
Accumulated Other Comprehensive Income (Loss) [Line Items]                              
Exercise price [9] $ 1.64                            
[1] On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 warrants previously issued by LACQ (subsequently in December 2022 and August 2023, 7,782 and 7,310 warrants, respectively, were cancelled). The warrants provide holders the right to purchase common stock at a strike price of between $2,400.00 and $2,760.00 per share and expire June 30, 2026, five years following the completion of the Business Combination. A total of 41,666 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. The remaining 21,993 warrants are private warrants with restrictions on transfer and which have the right to a cashless exercise at the option of the holder.
[2] On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 warrants to purchase common stock pursuant to the share subscription facility. The warrants have a three-year life and an initial exercise price of $2,402.40 per share. The warrants have been subject to multiple exercise price reductions as required by a down-round adjustment feature of the warrant, due to common stock issued at prices below the then current exercise price. The adjustments have progressed from the original exercise price of $2,402.40 per share to the current exercise price at June 30, 2024 of $1.06 per share. The difference in fair value of the existing warrant prior to the adjustment and the value of the warrant after (utilizing a Black-Scholes model) is reflected on the consolidated statement of operations as a deemed dividend.
[3] On September 24, 2021 and November 5, 2021, the Company issued 1,507 and 3,011 warrants in connection with the issuance of the 2021 Notes. The warrants were immediately exercisable with an exercise price of $1,831.20 (subject to downward revision protection in the event the Company makes certain issuances of common stock at prices below the conversion price) and expire on September 23, 2026 and November 4, 2026, respectively. As a result of the issuance of the 2022 Notes in July 2022, the exercise price of these warrants was adjusted down to $187.20. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
[4] On July 1, 2022 and August 9, 2022, the Company issued 19,450 warrants each in connection with the issuance of the 2022 Notes. The warrants were immediately exercisable with an exercise price of $170.04 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on June 29, 2027 and August 8, 2027, respectively. As a result of the issuance of shares and warrants in connection with the December 2022 public offering, the exercise price of these warrants was adjusted down to $24.07. On May 12, 2023, in exchange for $0.125 per outstanding warrant, the Company amended the warrants to reduce their exercise price to $3.64.
[5] On December 9, 2022, the Company issued 549,993 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $16.80 (subject to downward revision protection in the event the Company makes certain issuance of common stock at prices below the conversion price) and expire on December 9, 2027. On May 12, 2023, in exchange for $0.125 per applicable warrant, the Company amended 166,667 of these warrants to reduce their exercise price to $3.64.
[6] On February 6, 2023, the Company issued 318,451 equity classified warrants in connection with a public offering. The warrants were immediately exercisable with an exercise price of $8.58 - $12.60 and expire on February 2, 2028, and August 7, 2028.
[7] On May 12, 2023, the Company issued 3,727,813 equity classified warrants (Series A-1, A-2, and placement agent warrants) in connection with a public offering. The warrants were immediately exercisable with an exercise price of $3.64 - $4.86 and expire on November 12, 2024, May 10, 2028, and May 12, 2028. In connection to the Inducement Letter entered into February 12, 2024, certain existing warrant holders agreed to exercise 3,601,752 Series A-1 and A-2 warrants at a reduced exercise price of $1.31. The placement agent warrants remain outstanding as of June 30, 2024.
[8] On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 shares and 2,511,394 shares, respectively. The warrants were immediately exercisable with an exercise price of $1.5675 and expire on October 25, 2028 and November 28, 2028, respectively. In January 2024, a holder of the warrants exercised 1,323,904 warrants at an exercise price of $1.5675.
[9] On February 12, 2024, the Company issued 7,455,627 equity classified warrants (Series A Warrants, Series B Warrants and placement agent warrants) in connection with the Inducement Letter for the 2024 warrant inducement and related warrant restructuring. The Series A and Series B Warrants were immediately exercisable with an exercise price of $1.06 and expire on August 14, 2025 and May 12, 2028, respectively. The placement agent warrants were immediately exercisable with an exercise price of $1.6375 and expire on May 12, 2028.
v3.24.2.u1
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)
Jun. 30, 2024
$ / shares
Aug. 09, 2022
$ / shares
Jul. 01, 2022
$ / shares
Nov. 05, 2021
$ / shares
Sep. 24, 2021
$ / shares
Jul. 02, 2021
$ / shares
Jun. 30, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years           3 years 5 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 3,477.60            
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 2,400.00            
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 2,760.00            
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 3 years         3 years  
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 110.0            
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 0.5            
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants           3,477.60  
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 1.13            
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 1,029.60            
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants           2,402.40  
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 1.06            
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 680.23            
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 4 months 17 days            
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 2 years 6 months 29 days            
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants           110.0  
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 91.3            
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 140.5            
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants           0.5  
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 1.04            
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 5.43            
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants   127.20 136.80 540 1,077.60    
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants   170.04 170.04 1,831.20 1,831.20    
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years   5 years 5 years 5 years 5 years    
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants   102.8 98.9 94.1 94.1    
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants   3.0 2.9 1.0 1.0    
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 0.50            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 3.64            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 2 years 3 months            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 2 years 4 months 6 days            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 133.7            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 135.4            
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 4.6            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Exercise Price [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 3.64            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 3 years            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Expected term years 3 years 1 month 9 days            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 126.7            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 128.6            
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Risk Free Interest Rate [Member]              
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]              
Estimating fair value of warrants 4.4            
v3.24.2.u1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Feb. 12, 2024
Jun. 30, 2024
Jun. 30, 2024
Jan. 31, 2024
Dec. 31, 2023
Nov. 28, 2023
Oct. 25, 2023
May 12, 2023
Feb. 06, 2023
Dec. 09, 2022
Aug. 09, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jul. 02, 2021
Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Common stock, shares authorized   250,000,000 250,000,000   250,000,000                        
Preferred stock, shares authorized   1,500,000 1,500,000   1,500,000                        
Preferred stock par value   $ 0.0001 $ 0.0001   $ 0.0001                        
Preferred stock, shares issued   0 0   0                        
Preferred stock, shares outstanding   0 0   0                        
Warrants to purchase common shares                     19,450 19,450 3,011 1,507   4,608 78,751
Warrant exercise price $ 1.31 $ 1.06 $ 1.06 $ 1.5675       $ 3.64     $ 170.04 $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00   $ 2,760.00
Warrant maturity date                     Aug. 08, 2027 Jun. 29, 2027 Nov. 04, 2026 Sep. 23, 2026     Jun. 30, 2026
Legal fees $ 0.3                                
Warrants issue, description the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction.                                
Warrants to purchase common stock 252,123                                
Shares held in abeyance     666,144                            
Series A Warrants [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Warrants to purchase common shares 3,601,752                                
Warrant exercise price $ 1.06                                
Warrant maturity date Aug. 14, 2025                                
Series B Warrants [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Warrants to purchase common shares 3,601,752                                
Warrant exercise price $ 1.06                                
Warrant maturity date May 12, 2028                                
Warrant [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Common stock, shares authorized               166,667                  
Warrants to purchase common shares 3,601,752     1,323,904   2,511,394 1,255,697 3,727,813 318,451 549,993              
Share price $ 1.31                                
Warrant exercise price $ 1.6375 $ 1.5675 $ 1.5675     $ 1.5675 $ 1.5675 $ 0.125   $ 16.80              
Warrant maturity date May 12, 2028         Nov. 28, 2028 Oct. 25, 2028     Dec. 09, 2027              
Proceeds from warrants $ 4.7                                
Equity issuance costs $ 5.2                                
Warrant Inducement [Member]                                  
Accumulated Other Comprehensive Income (Loss) [Line Items]                                  
Shares held in abeyance   822,000 1,488,144                            
v3.24.2.u1
SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Option outstanding, beginning balance 581,314  
Weighted average exercise price. beginning balance $ 33.15  
Weighted average remaining contractual term 9 years 29 days 9 years 6 months 25 days
Aggregate intrinsic value, beginning balance  
Option outstanding, granted  
Weighted average exercise price, granted  
Aggregate intrinsic value, granted  
Option outstanding, exercised  
Weighted average exercise price, exercised  
Aggregate intrinsic value, exercised  
Option outstanding, expired or forfeited  
Weighted average exercise price, expired or forfeited  
Aggregate intrinsic value, expired or forfeited  
Option outstanding, ending balance 581,314 581,314
Weighted average exercise price, ending balance $ 33.15 $ 33.15
Aggregate intrinsic value, ending balance
Option, exercisable 580,188  
Weighted average exercise price, exercisable $ 32.28  
Aggregate intrinsic value, beginning balance  
Option vested or expected to vest 581,314  
Weighted average exercise price, vested or expected to vest $ 33.15  
Weighted average remaining contractual term, exercisable 9 years 29 days  
Aggregate intrinsic value, vested or expected to vest  
v3.24.2.u1
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)
Jun. 30, 2024
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Total shares of common stock reserved for future issuance 11,588,430
Warrant Outstanding [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Total shares of common stock reserved for future issuance 11,005,004
Share-Based Payment Arrangement, Option [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Total shares of common stock reserved for future issuance 581,314
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Total shares of common stock reserved for future issuance 2,112
v3.24.2.u1
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Aug. 31, 2023
Feb. 28, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock, capital shares reserved for future issuance 11,588,430   11,588,430      
Unrecognized stock based compensation $ 60,092   $ 60,092      
Weighted average period     11 months 12 days      
General and Administrative Expense [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share based compensation expense 18,658 $ 60,394 $ 42,146 $ 156,663    
Research and Development Expense [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share based compensation expense $ 7,891 $ 17,023 $ 17,610 $ 37,887    
2021 Omnibus Incentive Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock, capital shares reserved for future issuance         585,796 26,725
v3.24.2.u1
RELATED PARTIES (Details Narrative) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
Apr. 25, 2024
Jun. 30, 2024
Feb. 12, 2024
Jan. 31, 2024
Nov. 28, 2023
Oct. 25, 2023
Oct. 23, 2023
May 12, 2023
Dec. 09, 2022
Aug. 09, 2022
Jul. 01, 2022
Nov. 05, 2021
Sep. 24, 2021
Aug. 03, 2021
Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Warrants exercisable   0.4                          
Warrant, exercise price   $ 1.06 $ 1.31 $ 1.5675       $ 3.64   $ 170.04 $ 170.04 $ 1,831.20 $ 1,831.20 $ 2,400.00 $ 2,760.00
Warrant [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Warrant, exercise price   $ 1.5675 $ 1.6375   $ 1.5675 $ 1.5675   $ 0.125 $ 16.80            
Warrant, expiration date Apr. 25, 2025                            
Securities Purchase Agreement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Debt financing amount   $ 0.2                          
Warrant, exercise price             $ 1.5675                
Ensysce Biosciences (NASDAQ:ENSC)
過去 株価チャート
から 7 2024 まで 8 2024 Ensysce Biosciencesのチャートをもっと見るにはこちらをクリック
Ensysce Biosciences (NASDAQ:ENSC)
過去 株価チャート
から 8 2023 まで 8 2024 Ensysce Biosciencesのチャートをもっと見るにはこちらをクリック